


**8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-*i*]PURIN-5-ONE  
DERIVATIVES**

The invention relates to new therapeutically useful 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them.


EP 0 417 790 relates to s-triazolo[3,4-*i*]purines of general formula:



wherein

Y=Z

represents



where R<sup>4</sup> represents hydrogen, alkyl, an aromatic heterocyclic group which is optionally substituted with 1 or 2 substituents independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy and halogen, or substituted or unsubstituted aryl; and X<sup>2</sup> represents oxygen, sulfur or NH; each of R<sup>1</sup> and R<sup>2</sup> independently represents hydrogen, alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl; R<sup>3</sup> represents alkyl, cycloalkyl, aralkyl or substituted or unsubstituted aryl;

X<sup>1</sup> represents oxygen or sulfur;


--- represents a single bond or a double bond and

substituted or unsubstituted aryl means aryl which is optionally substituted with 1 or 2 substituents independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, trifluoromethyl, hydroxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>6</sub> alkylthio, nitro, halogen,

amino, C<sub>1</sub>-C<sub>6</sub> alkylamino, C<sub>1</sub>-C<sub>6</sub> alkanoylamino, aroylamine, carboxyl, C<sub>1</sub>-C<sub>6</sub> alkoxy carbonyl, C<sub>1</sub>-C<sub>6</sub> alkanoyl and aroyl; which possess a broncho-dilatory activity, diuretic activity, renal protecting activity and/or anti-amnesic activity.

We have now found that certain 8-(disubstituted)phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives are potent and selective inhibitors of cyclic guanosine 3'-5'-monophosphate specific phosphodiesterase (cGMP specific PDE) and more particularly inhibitors of phosphodiesterase 5 (PDE 5), and have utility in the treatment of angina, hypertension, congestive heart failure, stroke, asthma, male erectile dysfunction, female sexual dysfunction, glaucoma and irritable bowel syndrome.


Accordingly, the present invention provides compounds which are 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of formula (I):



(I)

wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent: hydrogen; an alkyl group which is unsubstituted or substituted by a hydroxy, alkoxy, alkylthio, amino, mono- or di-alkylamino, hydroxycarbonyl, alkoxy carbonyl, acylamino, carbamoyl or alkylcarbamoyl group; or a group of formula




wherein n is an integer from 0 to 4 and R<sup>6</sup> represents: a cycloalkyl group; a phenyl group which may be unsubstituted or substituted by one or more halogen atoms

or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, nitro, cyano or trifluoromethyl groups; or a 3 to 7-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, phenyl, alkoxycarbonyl, amino, mono-alkylamino, di-alkylamino or hydroxycarbonyl groups or one or more alkyl groups which may in turn be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, phenyl, alkoxycarbonyl, amino, mono- or di-alkylamino or hydroxycarbonyl groups;

either R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a 3 to 7-membered ring comprising a total of from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, oxoalkyl, carbamoyl, hydroxycarbonyl, alkoxycarbonyl, trifluoroacetyl, amino, mono- or di-alkylamino groups or an alkylene group, or one or more alkyl, alkenyl or alkynyl groups which may in turn be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, amino or mono- or di-alkylamino groups, or

R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, an amidino group or an alkyl, alkenyl or alkynyl group which may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, alkylthio, amino, mono- or di-alkylamino groups, or

R<sup>4</sup> represents hydrogen or an alkyl group and R<sup>5</sup> represents a group of formula



wherein n is an integer from 0 to 4 and R<sup>7</sup> represents: a cycloalkyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino,

alkylamido, nitro, cyano or trifluoromethyl groups; a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, nitro, cyano or trifluoromethyl groups; or a 3 to 7-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, phenyl, alkoxycarbonyl, amino, mono-alkylamino, di-alkylamino or hydroxycarbonyl groups or one or more alkyl groups which may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, phenyl, alkoxycarbonyl, amino, mono- or di-alkylamino or hydroxycarbonyl groups;

and pharmaceutically acceptable salts thereof.

The alkyl groups and moieties such as those present in the alkoxy, hydroxyalkoxy, alkylcarbonyl, mono- or di-alkylamino, alkylthio, alkylenedioxy, alkylamido and alkoxycarbonyl groups mentioned in relation to the groups  $R^1$  to  $R^7$  are usually "lower" alkyl that is containing from 1 to 6, particularly from 1 to 4 carbon atoms, the hydrocarbon chain being branched or straight. Preferred alkyl groups, and where relevant alkyl moieties, include methyl, ethyl, propyl, especially n-propyl, and butyl, especially n-butyl. Alkenyl and alkynyl groups mentioned in relation to formula (I) preferably have from 2 to 6 carbon atoms, most preferably from 2 to 4 carbon atoms.


Where an alkyl, alkenyl or alkynyl group, ring structure or moiety is described as being substituted by one or more substituents this preferably means from 1 to 3 substituents, more preferably one or two substituents.

The cycloalkyl groups mentioned in relation to the groups  $R^6$  and  $R^7$  are preferably  $C_{3-10}$  cycloalkyl groups, more preferably  $C_{3-7}$  cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl groups. In compounds of the invention wherein the cycloalkyl group is substituted, preferred substituents

include acetamido and mono- and di-alkylamino, most preferably mono- or di-ethylamino groups. The substituent group may be at any substitutable position of the cycloalkyl ring. Preferably the cycloalkyl ring is substituted at the 1-position.


The halogen atoms mentioned in relation to the groups  $R^4$  to  $R^7$  are preferably chlorine or fluorine atoms.

For compounds of the invention wherein  $R^1$ ,  $R^2$  or  $R^3$  represent a group of formula




$n$  may represent 0, 1, 2, 3, or 4, preferably 0, 1 or 2.

For compounds of the invention wherein  $R^6$  represents a 3 to 7-membered heterocyclic ring,  $R^6$  may be unsaturated or saturated and may represent for example a piperidyl, pyrrolidyl, azetidiny, aziridyl, piperaziny, morpholinyl, thiomorpholinyl, pyrrolyl, imidazolyl, imidazolidinyl, pyrazolinyl, indolinyl, isoindolinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indoliziny, isoindolyl, indolyl, indazolyl, purinyl, quinoliziny, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, quinuclidinyl, triazolyl, pyrazolyl, triazolyl, tetrazolyl or thienyl group, which group may be substituted or unsubstituted as defined above. In preferred compounds of the invention wherein  $R^1$ ,  $R^2$  or  $R^3$  represent a group of formula




and wherein  $R^6$  represents a 3 to 7-membered heterocyclic ring,  $R^6$  is a pyridyl, piperidyl, piperaziny, morpholinyl, triazolyl or tetrazolyl group.

In preferred compounds of the invention  $R^1$  represents: hydrogen; a  $C_1$ - $C_4$  alkyl group; or a group of formula




wherein n is 0, 1 or 2 and R<sup>6</sup> represents phenyl, pyridyl or morpholinyl. Most preferably, R<sup>1</sup> represents hydrogen or a methyl, ethyl, propyl, pyridyl, pyridylmethyl, benzyl or N-morpholinylmethyl group.

In preferred compounds of the invention R<sup>2</sup> represents: a C<sub>1</sub>-C<sub>5</sub> alkyl group especially a C<sub>1</sub>-C<sub>4</sub> alkyl group; a substituted C<sub>1</sub>-C<sub>5</sub> alkyl group; a C<sub>3</sub>-<sub>10</sub> cycloalkyl group; or a group of formula



wherein n is 0, 1 or 2 and R<sup>6</sup> represents an unsubstituted or substituted phenyl or pyridyl group. Most preferably R<sup>2</sup> represents an ethyl, propyl, n-butyl, i-butyl, n-pentyl, methoxyethyl, substituted or unsubstituted benzyl or 3-pyridylmethyl group.

In preferred compounds of the invention R<sup>3</sup> represents: a C<sub>1</sub>-C<sub>4</sub> alkyl group; a C<sub>3</sub>-<sub>10</sub> cycloalkyl group; or a group of formula



wherein n is 0, 1 or 2 and R<sup>6</sup> represents an unsubstituted or substituted phenyl or pyridyl group. Most preferably R<sup>3</sup> represents an ethyl, propyl or n-butyl group.

For compounds of the invention wherein R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a 3 to 7-membered ring comprising a total of from 1 to 4 heteroatoms, the ring may be saturated or unsaturated and is preferably selected from a piperidyl, pyrrolidyl, azetidyl, aziridyl, piperaziny, [1,4]diazepan-1-yl, morpholinyl, thiomorpholinyl, pyrrolyl, pyrazolyl, imidazolyl, imidazolidinyl, pyrazolinyl, indolinyl or isoindolinyl group, said group being unsubstituted or substituted as defined above. It is to be understood that when the substituent is an alkylene group it is attached

to the heterocyclic ring at any two substitutable positions which may be adjacent or not adjacent to each other. When the substitutable positions are not adjacent to each other, the alkylene group forms a bridging group.


5 The alkylene group preferably has from 1 to 5 carbon atoms.

In preferred compounds of the invention the ring formed by R<sup>4</sup>, R<sup>5</sup> and the nitrogen atom to which they are attached is a substituted or unsubstituted piperidyl, piperazinyl, 10 [1,4]diazepan-1-yl, morpholinyl, pyrazolyl, azetidiny, diazabicyclo[2.2.1]hept-2-yl or hexahydropyrrolo[2,1-  
alpyrazinyl group. Preferred substituent groups are C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, carbamoyl, amino, di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, (2-hydroxyethyl)methylamino, hydroxyl, 2,2,2-  
15 trifluoroethanoyl, 2,2,2-trifluoroethyl, formyl groups and hydroxyalkyl groups, alkoxyalkyl groups and hydroxyalkoxyalkyl groups wherein the alkyl moieties contain from 1 to 4 carbon atoms. Most preferably R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached  
20 represent a 4-hydroxypiperidyl, 4-carbamoylpiperidyl, 3-carbamoylpiperidyl, piperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-formylpiperazinyl, [1,4]-diazepan-1-yl, 4-methyl-[1,4]-diazepan-1-yl, 4-(2-hydroxyethyl)piperazinyl, 4-[2-(2-hydroxyethoxy)ethyl]piperazinyl, morpholinyl,  
25 aminopyrazolyl, diazabicyclo[2.2.1]hept-2-yl, 5-methyldiazabicyclo[2.2.1]hept-2-yl, 5-(2-hydroxyethyl)-diazabicyclo[2.2.1]hept-2-yl, 3(S)-methylpiperazinyl, 3(R)-methylpiperazinyl, (3R,5S)-3,5-dimethylpiperazinyl, (2R,5S)-2,5-dimethylpiperazinyl, (2S,5R)-2,5-dimethylpiperazinyl, 3-dimethylaminoazetidiny, 3-dimethylaminomethylazetidiny, 4-allylpiperazinyl, 4-propylpiperazinyl, hexahydropyrrolo[1, 2-a]pyrazin-2-yl, (3R,5S)-3,4,5-trimethylpiperazinyl, 4-(2-methoxyethyl)-  
30 piperazinyl, 4-(2-hydroxyethyl)[1,4]diazepan-1-yl, 4-(2-hydroxy-1-methylethyl)piperazinyl, 4-(2-hydroxy-1,1-dimethylethyl)piperazinyl, 4-(2,2,2-trifluoroethyl)-

10057347.013502  
piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(isopropyl)  
piperazinyl, 4-(2-ethoxyethyl)piperazinyl, 4-(2,2,2-  
trifluoroethanoyl)piperazinyl, 3-hydroxyazetidiny, 3-(2-  
hydroxyethyl)methylaminoazetidiny or 4-(2-hydroxyethyl)-  
5 piperidyl group.

For compounds of the invention wherein R<sup>4</sup> and R<sup>5</sup>  
independently represent hydrogen, an amidino group or an  
alkyl, alkenyl or alkynyl group which may be unsubstituted  
or substituted by one or more hydroxy, alkoxy, alkylthio,  
10 amino, mono- or di-alkylamino groups, R<sup>4</sup> and R<sup>5</sup> are  
preferably hydrogen or a C<sub>1</sub>-C<sub>4</sub> alkyl group which is  
unsubstituted or substituted by a hydroxy or dimethyl  
amino group, propyl group or an amidino group, most  
preferably R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen or a  
15 methyl, ethyl, propyl, hydroxyethyl, dimethylaminoethyl,  
propynyl, dimethylaminopropyl or amidino group.

For compounds of the invention wherein R<sup>4</sup> is hydrogen or  
alkyl and R<sup>5</sup> represents a group of formula




20 n may represent 0, 1, 2, 3, or 4, preferably 0, 1, 2 or 3.

For compounds of the invention wherein R<sup>7</sup> represents a 3  
to 7-membered heterocyclic ring, R<sup>7</sup> may be unsaturated or  
saturated and may represent for example a piperidyl,  
25 pyrrolidyl, azetidiny, aziridyl, piperazinyl,  
morpholinyl, thiomorpholinyl, pyrrolyl, imidazolyl,  
imidazolidiny, pyrazolinyl, indolinyl, isoindolinyl,  
pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indoliziny,  
isoindolyl, indolyl, indazolyl, purinyl, quinoliziny,  
30 isoquinolyl, quinolyl, phthalazinyl, naphthyridiny,  
quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl,  
quinuclidiny, triazolyl, pyrazolyl, triazolyl, tetrazolyl  
or thienyl group, which group may be substituted or  
unsubstituted. R<sup>7</sup> may alternatively represent an  
35 unsubstituted or substituted cycloalkyl or phenyl group as  
defined above.



In preferred compounds of the invention  $R^4$  is hydrogen or a  $C_1$ - $C_4$  alkyl group and  $R^5$  represents a group of formula



5

n is 0, 1, 2 or 3 and  $R^7$  is a pyridyl, piperidyl, piperazinyl, morpholinyl, triazolyl, tetrazolyl, pyrrolidinyl, 1-ethylaminocyclohex-1-yl, 1-diethylaminocyclohex-1-yl, 1-ethylaminocyclohept-1-yl, 1-diethylaminocyclohept-1-yl, 3,4-dimethoxyphenyl, 1-methyl-4-phenylpiperidin-4-yl, imidazolyl, 1-methylpiperid-4-yl, tetrahydrofuranyl, 2,2,6,6,-tetramethylpiperid-4-yl, 4-hydroxypiperid-4-yl, 1-acetamidocyclohept-1-yl, 1-methyl-3-azetidinyll or 4-methylpiperazin-1-yl group. Most preferred are the compounds wherein  $R^4$  represents hydrogen or a methyl or ethyl group and  $R^5$  represents a pyridyl, 1-morpholinylethyl, 1-piperidylethyl, 1-morpholinylpropyl, 1-pyrrolidylethyl, 1-ethylaminocyclohexylmethyl, 1-ethylaminocycloheptylmethyl, 1-diethylaminocyclohexylmethyl, 1-diethylaminocycloheptylmethyl, 2-(3,4-dimethoxyphenyl)ethyl, 1-methyl-4-phenylpiperidin-4-ylmethyl, 1H-[1,2,4]triazol-3-yl, pyridin-4-ylmethyl, 2-pyridin-2-ylethyl, 3-imidazol-1-ylpropyl, 1-methylpiperidin-4-yl, tetrahydrofuran-2-ylmethyl, 2,2,6,6-tetramethylpiperidin-4-ylmethyl, 1-acetamidocyclohept-1-ylmethyl, 1-methylazetidin-3-yl or 4-methylpiperazin-1-yl group.

Of outstanding interest are:

30


6-ethyl-8-[5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one,  
8-[2-butoxy-5-(4-methylpiperazine-1-sulfonyl)phenyl]-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one,

35

8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-{5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-[5-(4-methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
6-butyl-8-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one, and  
3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxy-*N*-pyridin-4-ylbenzenesulphonamide.  
8-[5-((*S*)-3-Methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-[5-((1*S*,4*S*)-5-Methyl-2,5-diazabicyclo[2.2.1]heptane-2-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-[5-(3-Dimethylaminomethylazetidide-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-[5-((3*R*,5*S*)-3,5-Dimethylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
*N*-(3-Dimethylamino-2,2-dimethylpropyl)-3-(oxopropyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide,  
8-{5-[4-(2-Hydroxyethyl)-[1,4]diazepane-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,  
8-{5-[4-(2-Hydroxy-1,1-dimethylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one,


6-Butyl-8-{5-[4-(2-hydroxy-1,1-dimethylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6,9-dihydro-[1,2,4]triazolo  
[3,4-*i*]purin-5-one

According to a further feature of the present  
invention, the 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]  
purin-5-ones of general formula (I) are prepared by  
reaction of a corresponding hydrazinopurine derivative of  
formula (II):



(II)


(wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as hereinbefore defined) with  
the corresponding carboxylic acid of the general formula  
(III):



(wherein R<sup>1</sup> is as hereinbefore defined) or a reactive  
derivative thereof. Preferred examples of a reactive  
derivative of the carboxylic acid (III) are the acid  
halide, orthoester or anhydride. The reaction may be  
carried out in a solvent, preferably a polar aprotic  
solvent, such as *N,N*-dimethylformamide, dioxane, acetone  
or tetrahydrofuran, in the presence of an organic base,  
preferably an amine base, such as triethylamine and at a  
temperature from 15°C to the boiling point of the solvent.  
The reaction can also be carried out in the absence of a  
solvent, in which case an excess of the carboxylic acid  
(III) or reactive derivative of the carboxylic acid (III)  
is used and the mixture is heated at a temperature from  
40°C to its boiling point. The thus obtained 8-phenyl-6,9-

10057847 013502  
202210 24275001  
dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one derivative is then isolated by usual methods known in the art.


The hydrazinopurines of general formula (II) are obtained by reaction of the 6-thioxopurines of the general formula (IV)



(IV)

(wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as hereinbefore defined) with hydrazine hydrate at a temperature from 80 to 150°C.


The 6-thioxopurines of general formula (IV) are obtained by reaction of the 8-phenylxanthines of general formula (V)



(V)


(wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are as hereinbefore defined) with phosphorus pentasulphide or Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide). The reaction is preferably carried out in a solvent, such as benzene, toluene, dioxane or pyridine, at a temperature from 40°C to the boiling point of the solvent.

The 8-phenylxanthines of general formula (V) are prepared from the corresponding compound of formula (VI):




(VI)

(wherein  $R^2$  and  $R^3$  are as defined above) by reaction with chlorosulphonic acid (preferably in excess), preferably under a nitrogen atmosphere and at a temperature from  $-51^{\circ}\text{C}$  to  $101^{\circ}\text{C}$  and where the solvent is the same chlorosulphonic acid. In this manner, the sulphonyl chloride of formula (VII):



(VII)


wherein  $R^2$  and  $R^3$  are as defined above, is obtained, which by further reaction with the corresponding amine (VIII):



(VIII)


wherein  $R^4$  and  $R^5$  are as defined above, produces the 8-phenylxanthine derivative of general formula (VI). The reaction is carried out in an organic solvent preferably a polar aprotic organic solvent such as dioxane, methylene chloride or tetrahydrofuran, at a temperature from 10°C to the boiling point of the solvent and in the presence of an organic base, preferably an amine base such as triethylamine.

The 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-ones derivatives of general formula (I) are also prepared according to a further feature of the present invention, from the corresponding phenylxanthine of formula (IX):




(IX)

(wherein  $R^1$ ,  $R^2$  and  $R^3$  are as hereinbefore defined) by reaction with chlorosulphonic acid (preferably in excess), preferably under a nitrogen atmosphere and at a temperature from -5°C to 10°C and where the solvent is the same chlorosulphonic acid. In this manner, the sulphonyl chloride of formula (X):




(X)

wherein  $R^1$ ,  $R^2$  and  $R^3$  are as defined above, is obtained, which by further reaction with the corresponding amine (VIII):




wherein  $R^4$  and  $R^5$  are as defined above, gives the 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivative of general formula (I). The reaction is carried out in an organic solvent preferably a polar aprotic organic solvent such as dioxane, methylene chloride or tetrahydrofuran, at a temperature from 10°C to 40°C and in the presence of an organic base, preferably an amine base such as triethylamine. The thus obtained 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivative is then isolated by the usual method known in the art.

The intermediate compounds of formula (IX) can be prepared by reaction of a corresponding hydrazinopurine derivative of formula (XI):



(XI)

(wherein  $R^2$  and  $R^3$  are as hereinbefore defined) and the corresponding carboxylic acid of the general formula (III):




(III)

(wherein  $R^1$  is as hereinbefore defined) or a reactive derivative of thereof. The reactive derivative of the carboxylic acid (III) is preferably the acid halide, orthoester or anhydride. The reaction can be carried out in a solvent, preferably a polar aprotic solvent, such as *N,N*- dimethylformamide, dioxane, acetone or tetrahydrofuran, in the presence of an organic base, preferably an amine base, such as triethylamine and at a temperature from 15°C to 40°C. The reaction can also be carried out in the absence of a solvent, in which case an excess of the carboxylic acid (III) or reactive derivative of the carboxylic acid (III) is used and the mixture is heated at a temperature from 40°C to its boiling point.

The hydrazinopurines of general formula (XI) are obtained by reaction of the 6-thioxopurines of the general formula (XII)






(XII)

(wherein  $R^2$  and  $R^3$  are as hereinbefore defined) with hydrazine hydrate at a temperature from 80 to 150°C.

The 6-thioxopurines of general formula (XII) are obtained by reaction of the 8-phenylxanthines of general formula (VI)



(VI)

(wherein  $R^2$  and  $R^3$  are as hereinbefore defined) with phosphorus pentasulphide or Lawesson's reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide). The reaction is preferably carried out in a solvent, such as benzene, toluene, dioxane or pyridine, at a temperature from 40°C to the boiling point of the solvent.

The 8-phenylxanthines of general formula (VI) can be prepared by reaction of the corresponding 5,6-diaminouracils and the corresponding salicylic acid derivatives by methods known per se, e.g. H. W. Hamilton et al., *J. Med. Chem.* **1985**, 28, 1071-1079 and references cited therein.

10057847.015503  
The 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one derivatives of formula (I) can be converted by methods known per se into pharmaceutically acceptable salts, preferably acid addition salts by treatment with organic or inorganic acids such as fumaric, tartaric, succinic or hydrochloric acid. Also 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one derivatives of formula (I) in which there is the presence of an acidic group, may be converted into pharmacologically acceptable by reaction with an alkali metal hydroxide or an organic base such as sodium or potassium hydroxide. The acid or alkali addition salts so formed may be interchanged with suitable pharmaceutically acceptable counter ions using process known per se.

15 The cyclic GMP specific phosphodiesterase (PDE 5) was isolated from human platelet lysates by ion exchange chromatography using a Mono-Q column. The enzyme activity was determined using 0.25 mM [3H]-cyclic GMP as substrate. The purification of the enzyme and the assessment of the PDE 5 inhibitory activity of our compounds were performed essentially as described by Gristwood *et al.*, *Br. J. Pharmacol.* **1992**, *105*, 985-991.

The results are shown in Table 1.

TABLE 1

Example	IC <sub>50</sub> (nM)
4	11
6	13
17	1.5
18	14
22	3.7
27	4
43	4
86	1.4
89	0.51
91	0.97
93	0.85
101	0.54
105	0.34
108	1.6
138	0.84

It can be seen from Table 1 that the compounds of  
formula (I) are potent inhibitors of cyclic GMP specific  
phosphodiesterase (PDE 5). Preferred 8-phenyl-6,9-  
dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of  
the invention possess an IC<sub>50</sub> value for the inhibition of  
PDE 5 (determined as defined above) of less than 30 nM,  
preferably less than 20 nM and most preferably less than  
15 nM. The 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-  
i]purin-5-one derivatives of the invention are useful in a  
the treatment of stable, unstable and variant angina,  
hypertension, pulmonary hypertension, congestive heart  
failure, renal failure, atherosclerosis, conditions of  
reduced blood vessel potency, peripheral vascular disease,  
vascular disorders (e.g. Raynaud=s disease), stroke,  
bronchitis, chronic asthma, allergic asthma, allergic  
rhinitis, glaucoma, male erectile dysfunction, female  
sexual dysfunction and diseases characterised by disorders  
of gut motility, e.g. irritable bowel syndrome.

Accordingly, the 8-phenyl-6,9-dihydro-  
[1,2,4]triazolo[3,4-*i*]purin-5-one derivatives of the  
invention and pharmaceutically acceptable salts thereof,  
and pharmaceutical compositions comprising such compound  
5 and/or salts thereof, may be used in a method of treatment  
of disorders of the human body which comprises  
administering to a patient requiring such treatment an  
effective amount of a 8-phenyl-6,9-dihydro-  
[1,2,4]triazolo[3,4-*i*]purin-5-one derivative of the  
10 invention or a pharmaceutically acceptable salt thereof.

The present invention also provides pharmaceutical  
compositions which comprise, as an active ingredient, at  
least a 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-  
5- one derivative of formula (I) or a pharmaceutically  
15 acceptable salt thereof in association with a  
pharmaceutically acceptable excipient such as a carrier or  
diluent. The active ingredient may comprise 0.001% to 99%  
by weight, preferably 0.01% to 90% by weight of the  
composition depending upon the nature of the formulation  
20 and whether further dilution is to be made prior to  
application. Preferably the compositions are made up in a  
form suitable for oral, topical, nasal, rectal,  
percutaneous or injectable administration.

The pharmaceutically acceptable excipients which are  
25 admixed with the active compound, or salts of such  
compound, to form the compositions of this invention are  
well-known per se and the actual excipients used depend  
inter alia on the intended method of administering the  
compositions.

30 Compositions of this invention are preferably adapted  
for injectable and per os administration. In this case,  
the compositions for oral administration may take the form  
of tablets, retard tablets, sublingual tablets, capsules  
or liquid preparations, such as mixtures, elixirs, syrups  
35 or suspensions, all containing the compound of the  
invention; such preparations may be made by methods well-  
known in the art.

10057847 012502  
The diluents which may be used in the preparation of the compositions include those liquid and solid diluents which are compatible with the active ingredient, together with colouring or flavouring agents, if desired. Tablets or capsules may conveniently contain between 2 and 500 mg of active ingredient or the equivalent amount of a salt thereof.

The liquid composition adapted for oral use may be in the form of solutions or suspensions. The solutions may be aqueous solutions of a soluble salt or other derivative of the active compound in association with, for example, sucrose to form a syrup. The suspensions may comprise an insoluble active compound of the invention or a pharmaceutically acceptable salt thereof in association with water, together with a suspending agent or flavouring agent.

Compositions for parenteral injection may be prepared from soluble salts, which may or may not be freeze-dried and which may be dissolved in pyrogen free aqueous media or other appropriate parenteral injection fluid.

Effective doses are normally in the range of 10-600 mg of active ingredient per day. Daily dosage may be administered in one or more treatments, preferably from 1 to 4 treatments, per day.

The syntheses of the compounds of the invention and of the intermediates for use therein are illustrated by the following Examples (including Preparation Examples (Preparations 1-37)) which do not limit the scope of the invention in any way.

<sup>1</sup>H Nuclear Magnetic Resonance Spectra were recorded on a Varian Gemini 300 spectrometer. Low Resolution Mass Spectra (m/z) were recorded on a Micromass ZMD mass spectrometer using ESI ionization. Melting points were recorded using a Perkin Elmer DSC-7 apparatus. The chromatographic separations were obtained using a Waters 2690 system equipped with a Symmetry C18 (2.1 x 10 mm, 3.5 μM) column. The mobile phase was formic acid (0.4 mL),

ammonia (0.1 mL), methanol (500 mL) and acetonitrile (500 mL) (A) and formic acid (0.46 mL), ammonia (0.115 mL) and water (1000 mL) (B): initially from 0% to 95% of B in 20 min, and then 4 min. with 95% of B. The reequilibration time between two injections was 5 min. The flow rate was 0.4 mL/min. The injection volume was 5 µL. Diode array chromatograms were collected at 210 nm.

#### PREPARATION EXAMPLES

##### PREPARATION 1

##### **8-(2-Ethoxyphenyl)-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4- i]purin-5-one**

a) A solution of 2-ethoxybenzoyl chloride (12.0 g, 65 mmol) in dimethylformamide (10 mL) was added dropwise to a stirred solution of 5,6-diamino-1-ethyl-1*H*-pyrimidine-2,4-dione (10.4 g, 61 mmol) and triethylamine (9.8 mL, 65 mmol) in dimethylformamide (250 mL). The resulting mixture was stirred for 20 hours at room temperature, then evaporated under reduced pressure. Aqueous sodium hydroxide solution (1N, 98 mL, 98 mmol) was added and the mixture heated under reflux for 6 hours. The resulting solution was acidified with 1N hydrochloric acid and the precipitate collected and dried by suction to give 8-(2-ethoxyphenyl)-3-ethyl-3,7-dihydropurine-2,6-dione as a beige solid (7.0 g, 72%).

b) Phosphorus pentasulphide (5.5 g, 12.4 mmol) was added portionwise to a stirred suspension of the above compound (7.0 g, 23.3 mmol) in pyridine (115 mL) and the resulting mixture stirred under reflux for 3 hours, then evaporated under reduced pressure. The residue was triturated with hydrochloric acid (2N, 100 mL) and the precipitate collected by filtration and dried under vacuum to yield 8-(2-ethoxyphenyl)-3-ethyl-6-mercapto-3,7-dihydropurin-2-one (6.9 g, 95%) as a pale brown solid.

c) A stirred mixture of the above compound (6.9 g, 21.8 mmol) and hydrazine monohydrate (100 mL) was heated

to 130 1C for 3 hours. The resulting mixture was cooled and the precipitate collected by filtration and washed with water and ethanol, then dried under vacuum to yield 8-(2-ethoxyphenyl)-3-ethyl-6-hydrazino-3,7-dihydropurin-2-one (6.6 g, 97%) as an off-white solid.

d) A stirred mixture of the above compound (6.6 g, 21.0 mmol) and formic acid (110 mL) was heated under reflux for 2 hours. The resulting solution was concentrated under vacuum and the residue partitioned between dichloromethane and aqueous sodium bicarbonate solution, then the organic phase separated, washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to yield the title product (5.4 g, 79%) as an off-white solid.

$\delta$  (DMSO-d<sub>6</sub>): 1.38 (3H,t), 1.49 (3H,t), 4.27 (4H,m), 7.08 (1H,t), 7.21 (1H,d), 7.47 (1H,t), 7.97 (1H,d), 9.21 (1H,s).

#### PREPARATION 2

#### **4-Ethoxy-3-(6-ethyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)benzenesulphonyl chloride**

The title compound of Preparation 1 (5.4 g, 16.6 mmol) was added portionwise to neat ice-cooled chlorosulphonic acid (16 mL) and the resulting mixture stirred at 0 1C for 30 minutes and at room temperature overnight. The reaction mixture was carefully poured into stirred ice-water and the precipitate collected by filtration and dried under reduced pressure to yield the title compound (6.4 g, 91%) as a white solid.

$\delta$  (DMSO-d<sub>6</sub>): 1.42 (6H,m), 4.33 (2H,q), 4.42 (2H,q), 7.23 (1H,d), 7.73 (1H,d), 8.39 (1H,s), 9.59 (1H,s).

#### PREPARATION 3

#### **6-Ethyl-8-(2-propoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (51% overall) from 5,6-diamino-1-ethyl-1H-pyrimidine-2,4-dione and 2-

propoxybenzoyl chloride by the procedure described in Preparation 1.

5  $\delta$  (DMSO-d<sub>6</sub>): 1.15 (t, 3 H), 1.51 (t, 3 H), 2.05 (m, 2 H), 4.22 (t, 2 H), 4.44 (q, 2 H), 7.05 (d, 1 H), 7.12 (t, 1 H), 7.42 (t, 1 H), 8.40 (d, 1 H), 8.95 (s, 1 H), 11.40 (bs, 1 H).

#### PREPARATION 4

10 **3-(6-Ethyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl chloride**

Obtained as a white solid (74%) from the title compound of Preparation 3, using the procedure described in Preparation 2.

15  $\delta$  (DMSO-d<sub>6</sub>): 0.95 (t, 3 H), 1.39 (t, 3 H), 1.82 (m, 2 H), 4.33 (m, 4 H), 7.22 (d, 1 H), 7.75 (d, 1 H), 8.28 (s, 1 H), 9.55 (s, 1 H), 14.4 (bs, 1 H).

#### PREPARATION 5

20 **8-(2-Butoxyphenyl)-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (70% overall) from 5,6-diamino-1-ethyl-1H-pyrimidine-2,4-dione and 2-butoxybenzoyl chloride by the procedure described in Preparation 1.

25  $\delta$  (DMSO-d<sub>6</sub>): 1.05 (t, 3 H), 1.51 (m, 5 H), 1.95 (m, 2 H), 4.25 (t, 2 H), 4.45 (q, 2 H), 7.05 (d, 1 H), 7.13 (t, 1 H), 7.42 (t, 1 H), 8.40 (d, 1 H), 8.95 (s, 1 H), 11.55 (bs, 1 H).

#### 30 PREPARATION 6

**4-Butoxy-3-(6-ethyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)benzenesulphonyl chloride**

Obtained as a white solid (42%) from the title compound of Preparation 5, using the procedure described  
35 in Preparation 2.



205747 013502  
205747 013502  
205747 013502  
 $\delta$  (DMSO-d6): 0.95 (t, 3 H), 1.40 (m, 5 H), 1.80 (m, 2 H), 4.32 (m, 4 H), 7.22 (d, 1 H), 7.75 (d, 1 H), 8.38 (s, 1 H), 9.55 (s, 1 H), 13.0 (bs, 1 H).

5 PREPARATION 7

**8-(2-Ethoxyphenyl)-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one**

Obtained as a white solid (28% overall) from 5,6-diamino-1-propyl-1*H*-pyrimidine-2,4-dione and 2-ethoxybenzoyl chloride by the procedure described in Preparation 1.

$\delta$  (DMSO-d6): 0.96 (3H,t), 1.41 (3H,t), 1.83 (2H,m), 4.18 (2H,t), 4.28 (2H,q), 7.09 (1H,t), 7.20 (1H,d), 7.46 (1H,t), 7.93 (1H,d), 9.21 (1H,s).

15

PREPARATION 8

**4-Ethoxy-3-(5-oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl)benzenesulphonyl chloride**

Obtained as a white solid (73%) from the title compound of Preparation 7, using the procedure described in Preparation 2.

$\delta$  (DMSO-d6): 0.99 (3H,t), 1.42 (3H,t), 1.89 (2H,m), 4.22 (2H,t), 4.32 (2H,q), 7.19 (1H,d), 7.69 (1H,d), 8.26 (1H,s), 9.33 (1H,s).

25

PREPARATION 9

**8-(2-Propoxyphenyl)-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one**

Obtained as a beige solid (21% overall) from 5,6-diamino-1-propyl-1*H*-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1.

$\delta$  (DMSO-d6): 0.96 (3H,t), 0.99 (3H,t), 1.83 (4H,m), 4.17 (4H,m), 7.10 (1H,t), 7.22 (1H,d), 7.49 (1H,t), 7.96 (1H,d), 9.22 (1H,s).

35

PREPARATION 10

**3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl chloride**

Obtained as a white solid (100%) from the title compound of Preparation 9, using the procedure described in Preparation 2.

$\delta$  (DMSO-d<sub>6</sub>): 0.98 (6H,m), 1.88 (4H,m), 4.26 (4H,m), 7.23 (1H,d), 7.71 (1H,d), 8.30 (1H,s), 9.50 (1H,s).

PREPARATION 11

**6-Butyl-8-(2-ethoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as an off-white solid (49% overall) from 5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione and 2-ethoxybenzoyl chloride by the procedure described in Preparation 1.

$\delta$  (CDCl<sub>3</sub>): 1.02 (3H,t), 1.48 (2H,m), 1.63 (3H,t), 1.88 (2H,m), 4.39 (4H,m), 7.07 (1H,d), 7.16 (1H,t), 7.42 (1H,d), 8.41 (1H,d), 8.93 (1H,s), 11.37 (1H,bs).

PREPARATION 12

**3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-ethoxybenzenesulphonyl chloride**

Obtained as a white solid (90%) from the title compound of Preparation 11, using the procedure described in Preparation 2.

$\delta$  (CDCl<sub>3</sub>): 0.96 (3H,t), 1.42 (5H,m), 1.82 (2H,m), 4.28 (2H,t), 4.39 (2H,q), 7.20 (1H,d), 7.72 (1H,d), 8.29 (1H,s), 9.43 (1H,s).

PREPARATION 13

**6-Butyl-8-(2-propoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a beige solid (41% overall) from 5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1.



PREPARATION 17

**3-Methyl-8-(2-propoxyphenyl)-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

A mixture of 8-(2-propoxyphenyl)-3-propyl-6-hydrazino-3,7-dihydropurin-2-one (1.0 g, 2.9 mmol, see Preparation 9) and triethyl orthoacetate (10 mL) was heated under reflux for 2 h. The resulting mixture was cooled and the precipitate collected by filtration and washed with water and ethanol, then dried under vacuum to yield the title compound (0.82 g, 77%) as an off-white solid.

$\delta$  (DMSO-d<sub>6</sub>): 0.92 (3H, t), 0.96 (3H, t), 1.82 (4H, m), 2.77 (3H, s), 4.24 (4H, m), 7.08 (1H, t), 7.20 (1H, d), 7.45 (1H, t), 7.92 (1H, d)

PREPARATION 18

**3-(3-Methyl-5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonyl chloride**

Obtained as a white solid (88%) from the title compound of Preparation 17, using the procedure described in Preparation 2.

$\delta$  (CDCl<sub>3</sub>): 1.10 (4H, m), 1.96 (2H, m), 2.09 (2H, m), 2.96 (3H, s), 4.32 (2H, t), 4.48 (2H, t), 7.28 (1H, d), 8.09 (1H, d), 9.07 (1H, s), 11.8 (1H, bs)

PREPARATION 19

**6-Hydrazino-8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurin-2-one**

a) Phosphorus pentasulphide (0.7 g, 3.1 mmol) was added portionwise to a stirred suspension of 8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurine-2,6-dione (1.5 g, 23.3 mmol) in pyridine (15 mL) and the resulting mixture stirred under reflux for 3 hours, then evaporated under reduced pressure to give crude 8-(2-propoxyphenyl)-3-propyl-6-mercapto-3,7-

20537847-012302  
dihydropurin-2-one (1.38 g) which was used directly in the next step.

5         $\delta$  (DMSO-d<sub>6</sub>): 0.89 (3H, t), 1.03 (3H, t), 1.75 (2H, m), 1.82 (2H, m), 2.15 (3H, s), 2.37 (4H, m), 2.92 (4H, m), 3.97 (2H, t), 4.20 (2H, t), 7.42 (1H, d), 7.82 (1H, d), 8.16 (1H, s), 12.34 (1H, bs), 12.67 (1H, bs).

10        b) A stirred mixture of the above compound (1.38 g) and hydrazine monohydrate (15 mL) was heated to 130 °C for 3 hours. The resulting mixture was cooled and the precipitate collected by filtration and washed with water and ethanol, then dried under vacuum to yield 6-hydrazino-8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurin-2-one (1.08 g, 70% overall) as an off-white solid.

15         $\delta$  (DMSO-d<sub>6</sub>): 0.89 (3H, t), 1.04 (3H, m), 1.70 (2H, m), 1.89 (2H, m), 2.13 (3H, s), 2.36 (4H, m), 2.91 (4H, m), 3.96 (2H, m), 4.28 (2H, m), 7.51 (1H, d), 7.81 (1H, d), 8.51 (1H, s).

20        PREPARATION 20

**6-Hydrazino-8-[5-(piperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-1,3,6,7-tetrahydropurin-2-one**

25        Obtained as a beige solid (10% overall) from 8-[5-(piperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurine-2,6-dione by the procedure described in Preparation 19.

30         $\delta$  (DMSO-d<sub>6</sub>): 0.89 (3H, t), 1.06 (3H, m), 1.72 (2H, m), 1.91 (2H, m), 2.71 (4H, m), 2.82 (4H, m), 3.96 (2H, m), 4.28 (2H, m), 7.51 (1H, d), 7.88 (1H, d), 8.52 (1H, s).

PREPARATION 21

**6-Hydrazino-8-[5-(4-methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-3-propyl-1,3,6,7-tetrahydropurin-2-one**

35        Obtained as an off-white solid (91% overall) from 8-[5-(4-methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurine-2,6-dione by the procedure described in Preparation 19.

$\delta$  (DMSO- $d_6$ ): 0.89 (3H, t), 1.04 (3H, m), 1.72 (4H, m), 1.92 (2H, m), 2.22 (3H, s), 2.4-2.6 (6H, m), 3.38 (4H, m), 3.98 (2H, t), 4.28 (2H, t), 7.44 (1H, d), 7.86 (1H, d), 8.58 (1H, s).

5

Obtained as a beige solid (16% overall) from 8-[5-(morpholine-4-sulfonyl)-2-propoxyphenyl]-3-propyl-3,7-dihydropurine-2,6-dione by the procedure described in Preparation 19.

PREPARATION 23

20            Obtained as a beige solid (71% overall) 8-[2-butoxy-5-(4-methylpiperazine-1-sulfonyl)phenyl]-3-propyl-3,7-dihydropurine-2,6-dione by the procedure described in Preparation 19.

PREPARATION 24

Obtained as a beige solid (30% overall) from 8-[2-butoxy-5-(morpholine-4-sulfonyl)phenyl]-3-propyl-3,7-dihydropurine-2,6-dione by the procedure described in Preparation 19.

PREPARATION 25

**8-(2-Propoxyphenyl)-6-pyridin-2-ylmethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a beige solid (19% overall) from 5,6-diamino-1-pyridin-2-ylmethyl-1H-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1.

PREPARATION 26

**3-(5-Oxo-6-pyridin-2-ylmethyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonyl chloride**

Obtained as a white solid (65%) from the title compound of Preparation 25, using the procedure described in Preparation 2.

PREPARATION 27

**6-Butyl-8-(2-propoxyphenyl)-3-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (28% overall) from 5,6-diamino-1-butyl-1H-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1, using trimethyl orthobutyrate instead of formic acid in the last step.

PREPARATION 28

**3-(6-Butyl-5-oxo-3-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonyl chloride**

Obtained as a white solid (86%) from the title compound of Preparation 27, using the procedure described in Preparation 2.

PREPARATION 29

**6-Isobutyl-8-(2-propoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (21% overall) from 5,6-diamino-1-isobutyl-1H-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1.

5            $\delta$  (DMSO-d<sub>6</sub>): 0.93 (9H, m), 1.80 (2H, m), 2.36 (1H, m), 4.02 (2H, d), 4.12 (2H, t), 7.09 (1H, t), 7.18 (1H, d), 7.44 (1H, t), 7.92 (1H, d), 9.20 (1H, s).

#### PREPARATION 30

10   **3-(6-Isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonyl chloride**

Obtained as a white solid (62%) from the title compound of Preparation 29, using the procedure described in Preparation 2.

15            $\delta$  (DMSO-d<sub>6</sub>): 1.01 (9H, m), 1.86 (2H, m), 2.36 (1H, m), 4.06 (2H, d), 4.19 (2H, t), 7.18 (1H, d), 7.66 (1H, d), 8.18 (1H, s), 9.27 (1H, s).

#### PREPARATION 31

20   **6-Pentyl-8-(2-propoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (19% overall) from 5,6-diamino-1-pentyl-1H-pyrimidine-2,4-dione and 2-propoxybenzoyl chloride by the procedure described in Preparation 1.

25            $\delta$  (DMSO-d<sub>6</sub>): 0.83 (3H, t), 0.96 (3H, t), 1.33 (4H, m), 1.82 (4H, m), 4.15 (4H, m), 7.06 (1H, t), 7.19 (1H, d), 7.42 (1H, t), 7.91 (1H, d), 9.19 (1H, s).

#### PREPARATION 32

30   **3-(5-Oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl chloride**

Obtained as a white solid (55%) from the title compound of Preparation 31, using the procedure described in Preparation 2.

35



10037847-013503  
 $\delta$  (DMSO-d<sub>6</sub>): 0.88 (3H, m), 0.98 (3H, t), 1.38 (4H, m),  
1.82 (4H, m), 4.26 (4H, m), 7.20 (1H, d), 7.68 (1H, d),  
8.22 (1H, s), 9.38 (1H, s).

5 PREPARATION 33

**6-(2-Methoxyethyl)-8-(2-propoxyphenyl)-6,9-dihydro-  
[1,2,4]triazolo[3,4-*i*]purin-5-one**

Obtained as a white solid (65% overall) 5,6-diamino-  
1-(2-methoxyethyl)-1*H*-pyrimidine-2,4-dione and 2-  
10 propoxybenzoyl chloride by the procedure described in  
Preparation 1.

PREPARATION 34

**3-[6-(2-Methoxyethyl)-5-oxo-6,9-dihydro-5*H*-  
15 [1,2,4]triazolo[3,4-*i*]purin-8-yl]-4-propoxybenzenesulfonyl  
chloride**

Obtained as a white solid (95%) from the title  
compound of Preparation 33, using the procedure described  
in Preparation 2.

20

PREPARATION 35

**Azetidin-3-ylmethyldimethylamine, dihydrochloride**

a) A solution of 1-(1,1-diphenylmethyl)azetidine-3-  
carbonitrile (7.8 g, 31.4 mmol) in 30 mL of  
25 tetrahydrofuran was slowly added to a suspension of  
lithium aluminium hydride (4.0 g, 105 mmol) in  
tetrahydrofuran under nitrogen and the resulting mixture  
was stirred under reflux for one hour. On cooling, the  
mixture was treated dropwise with water (4 mL), aqueous  
30 sodium hydroxide (4 mL, 4N), and water (12 mL) and  
filtered. The filtrate was concentrated under reduced  
pressure to yield 3-(aminomethyl)-1-(1,1-  
diphenylmethyl)azetidine as a white solid (5.2 g, 73%).

b) A mixture of 3-(aminomethyl)-1-(1,1-diphenyl  
35 methyl)azetidine (10.9 g, 43 mmol), formaldehyde (21.8 mL)  
and formic acid (21.8 mL) was stirred under reflux for one  
hour and then evaporated under reduced pressure. The

resulting residue was mixed with ice, basified with aqueous sodium hydroxide 2N and extracted with dichloromethane. The organic solution was washed with water, brine, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to yield [1- (1,1-diphenylmethyl)azetidin-3-ylmethyl]dimethylamine (10.4 g, 86%) as an oil.

$\delta$  (CDCl<sub>3</sub>): 2.16 (6H, s), 2.44 (2H, d), 2.6-2.8 (4H, m), 3.38 (2H, t), 4.32 (1H, s), 7.1-7.3 (10 H, m).

c) Hydrogen chloride in methanol was added to a mixture of [1-(1,1-diphenylmethyl)azetidin-3-ylmethyl]dimethylamine (9.9 g, 35 mmol) in methanol (150 mL) until pH = 4. Palladium hydroxide (1.5 g, 20%) was added and the resulting mixture hydrogenated at room temperature at 50 p.s.i. for 4 days. The mixture was filtered through Celite and the filtrate evaporated under reduced pressure to give the title compound (5.0 g, 76%) as a white solid.

$\delta$  (DMSO-d<sub>6</sub>): 2.72 (6H, s), 3.2-4.1 (8H, m).

#### PREPARATION 36

##### **(1*S*,4*S*)-2-(2,5-Diazabicyclo[2.2.1]hept-2-yl)ethanol, dihydrochloride**

a) A mixture of (1*S*,4*S*)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid *tert*-butyl ester (0.5 g, 2.52 mmol), 2-(2-bromoethoxy)tetrahydropyran (0.42 mL, 2.77 mmol) and potassium carbonate (1.2 g, 8.82 mmol) in 4-methylpentan-2-one was stirred under reflux overnight. The resulting mixture was evaporated under reduced pressure and the residue was partitioned between water and dichloromethane. The organic layer was washed with brine, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to yield 5-[2-(tetrahydro-pyran-2-yloxy)ethyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid *tert*-butyl ester (0.80 g, quantitative) as an oil.

b) A mixture of 5-[2-(tetrahydro-pyran-2-yloxy)ethyl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic

acid *tert*-butyl ester (0.80 mmol, 2.4 mmol) and aqueous hydrochloric acid (2 mL, 2N) in ethanol (10 mL) was stirred under reflux for one hour and then evaporated under reduced pressure to yield crude (1*S*,4*S*)-2-(2,5-Diazabicyclo[2.2.1]hept-2-yl)ethanol, dihydrochloride (0.51 g) as a dark oil which was used in the next step without further purification.

#### PREPARATION 37

##### 2-Methyl-2-piperazin-1-ylpropan-1-ol

a) A mixture of piperazine-1-carboxylic acid benzyl ester (8.8 g, 40 mmol), 2-bromo-2-methylpropionic acid ethyl ester and potassium carbonate was stirred at 150 °C for 24 h. On cooling, the resulting mixture was partitioned between dichloromethane and water. The organic layer was washed with brine, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to give 4-(1-Ethoxycarbonyl-1-methyl-ethyl)-piperazine-1-carboxylic acid benzyl ester (10.2 g, 77%) as an oil.

b) A solution of 4-(1-ethoxycarbonyl-1-methyl-ethyl)-piperazine-1-carboxylic acid benzyl ester (3.5 g, 10.5 mmol) in 10 mL of dry ether was slowly added to a suspension of lithium aluminium hydride (0.3 g, 105 mmol) in tetrahydrofuran at -15 °C under nitrogen and the resulting mixture was stirred at 0° C for 3 hours. On cooling, the mixture was treated dropwise with water (0.3 mL), aqueous sodium hydroxyde (0.3 mL, 4N), and water (0.9 mL) and filtered. The filtrate was concentrated under reduced pressure to yield 4-(2-hydroxy-1,1-dimethylethyl)piperazine-1-carboxylic acid benzyl ester as a white solid (1.2 g, 41%).

c) A mixture of 4-(2-hydroxy-1,1-dimethylethyl)piperazine-1-carboxylic acid benzyl ester (3.0 g, 10.3 mmol) in methanol (70 mL) and palladium on charcoal (0.5 g, 10%) was hydrogenated at room temperature at 40 p.s.i. overnight. The mixture was filtered through












Celite and the filtrate evaporated under reduced pressure to give the title compound (1.55 g, 98%) as a white solid.














$\delta$  (DMSO-d<sub>6</sub>): 0.92 (6H, s), 2.52 (4H, m), 2.75 (4H, m), 3.23 (2H, s), 4.8 (2H, bs).















2025042601













EXAMPLES

TABLE 2














Example No	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	NR <sup>4</sup> R <sup>5</sup>
1	H	Et	Et	
2	H	Et	Et	
3	H	Et	Pr	
4	H	Et	Pr	
5	H	Et	Pr	
6	H	Et	nBu	
7	H	Et	nBu	
8	H	Et	nBu	
9	H	Et	nBu	
10	H	Et	nBu	
11	H	Pr	Et	











12	H	Pr	Et	
13	H	Pr	Et	
14	H	Pr	Pr	
15	H	Pr	Pr	
16	H	Pr	Pr	
17	H	Pr	Pr	
18	H	Pr	Pr	
19	H	Pr	Pr	
20	H	Pr	Pr	
21	H	Pr	Pr	
22	H	Pr	Pr	
23	H	Pr	Pr	
24	H	Pr	Pr	





25	H	Pr	Pr	
26	H	Pr	Pr	
27	H	Pr	Pr	
28	H	Pr	Pr	
29	H	Pr	Pr	
30	H	Pr	Pr	
31	H	Pr	nBu	
32	H	Pr	nBu	
33	H	nBu	Et	
34	H	nBu	Et	
35	H	nBu	Pr	
36	H	nBu	Pr	
37	H	nBu	Pr	
38	H	nBu	Pr	

39	H	nBu	Pr	
40	H	nBu	Pr	
41	H	nBu	Pr	
42	H	nBu	Pr	
43	H	nBu	Pr	
44	H	nBu	Pr	
45	H	nBu	Pr	
46	H	nBu	Pr	
47	H	nBu	Pr	
48	H	nBu	nBu	
49	H	nBu	nBu	
50	H	4-pyridyl-methyl	Pr	
51	Me	Pr	Pr	$N(CH_3)_2$














52	Me	Pr	Pr	
53	Me	Pr	Pr	
54	Pr	nBu	Pr	
55	Pr	nBu	Pr	
56	Pr	nBu	Pr	
57	Bn	Pr	Pr	
58	H	iBu	Pr	
59	H	iBu	Pr	
60	H	iBu	Pr	
61	H	iBu	Pr	
62	H	iBu	Pr	
63	H	iBu	Pr	
64	H	iBu	Pr	












65	H	iBu	Pr	
66	H	iBu	Pr	
67	H	iBu	Pr	
68	H	iBu	Pr	
69	H	n-Pn	Pr	
70	H	n-Pn	Pr	
71	H	n-Pn	Pr	
72	H	n-Pn	Pr	
73	H	n-Pn	Pr	
74	H	n-Pn	Pr	













Example No	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	NR <sup>4</sup> R <sup>5</sup>
75	H	n-Pn	Pr	
76	H	n-Pn	Pr	
77	H	n-Pn	Pr	
78	H	n-Pn	Pr	












10037847.0303

Example No	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	NR <sup>4</sup> R <sup>5</sup>
79	H	nPr	Et	
80	H	nPr	nPr	NH <sub>2</sub>
81	H	nPr	nPr	
82	H	nPr	nPr	
83	H	nPr	nPr	
84	H	nPr	nPr	
85	H	nPr	nPr	
86	H	nPr	nPr	
87	H	nPr	nPr	
88	H	nPr	nPr	
89	H	nPr	nPr	
90	H	nPr	nPr	
91	H	nPr	nPr	













92	H	nPr	nPr	
93	H	nPr	nPr	
94	H	nPr	nPr	
95	H	nPr	nPr	
96	H	nPr	nPr	
97	H	nPr	nPr	
98	H	nPr	nPr	
99	H	nPr	nPr	
100	H	nPr	nPr	
101	H	nPr	nPr	
102	H	nPr	nPr	

103	H	nPr	nPr	
104	H	nPr	nPr	
105	H	nPr	nPr	
106	H	nPr	nPr	
107	H	nPr	nPr	
108	H	nPr	nPr	
109	H	nPr	nPr	
110	H	nPr	nPr	
111	H	nPr	nPr	
112	H	nPr	nPr	
113	H	nPr	nPr	

114	H	nPr	nPr	
115	H	nPr	nPr	
116	H	nPr	nPr	$N(CH_3)_2$
117	H	nPr	nPr	
118	H	nPr	nPr	
119	H	nPr	nPr	
120	H	nPr	nPr	
121	H	nPr	nPr	
122	H	nPr	nPr	
123	H	nPr	nPr	
124	H	nPr	nPr	
125	H	nPr	nPr	
126	H	nPr	nPr	

127	H	nPr	nPr	
128	H	nPr	nPr	
129	H	nPr	nPr	
130	H	nPr	nPr	
131	H	nPr	nPr	
132	H	nBu	nPr	
133	H	nBu	nPr	
134	H	nBu	nPr	
135	H	nBu	nPr	
136	H	nBu	nPr	
137	H	nBu	nPr	



138	H	nBu	nPr	
139	H	iBu	nPr	
140	H	iBu	nPr	
141	H	iBu	nPr	
142	H	iBu	nPr	
143	H	$-(\text{CH}_2)_2\text{OCH}_3$	nPr	
144	H	$-(\text{CH}_2)_2\text{OCH}_3$	nPr	
145	H	$-(\text{CH}_2)_2\text{OCH}_3$	nPr	
146	H	$-(\text{CH}_2)_2\text{OCH}_3$	nPr	
147	H	nPn	nPr	
148	H	nPn	nPr	
149	H	nPn	nPr	

EXAMPLE 1

**8-[2-Ethoxy-5-(4-methylpiperazine-1-sulphonyl)phenyl]-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

To a mixture of the title compound of Preparation 2 (1.1 g, 2.4 mmol) and triethylamine (0.4 mL, 2.6 mmol) in dichloromethane (50 mL) was added dropwise a solution of 1-methylpiperazine (0.3 mL, 2.6 mmol) in dichloromethane (25 mL) and the resulting mixture was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane, washed with aqueous solution of sodium bicarbonate and water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure. The resulting crude residue on crystallisation from ethanol afforded the title compound (1.1 g, 93%) as a white solid.

m.p. 248 °C

δ (DMSO-d<sub>6</sub>): 1.38 (3H, t), 1.50 (3H, t), 2.15 (3H, s), 2.40 (4H, m), 2.93 (4H, m), 4.25 (2H, m), 4.40 (2H, m), 7.45 (1H, d), 7.90 (1H, d), 8.24 (1H, s), 9.28 (1H, s), 13.70 (1H, bs).

EXAMPLE 2

**8-{2-Ethoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (88 %) from the title compound of Preparation 2 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 230 °C

δ (DMSO-d<sub>6</sub>): 1.40 (3H, t), 1.50 (3H, t), 2.38 (2H, t), 2.50 (4H, m), 2.90 (4H, m), 3.40 (2H, m), 4.28 (2H, m), 4.40 (3H, m), 7.46 (1H, d), 7.90 (1H, d), 8.26 (1H, s), 9.27 (1H, s), 13.65 (1H, bs).

EXAMPLE 3

**6-Ethyl-8-[2-propoxy-5-(4-pyridylaminosulphonyl)]phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (46%) from the title compound of Preparation 2 and 4-aminopyridine following the procedure of example 1.

m.p. 279 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.39 (3H, t), 1.83 (2H, m),  
4.19 (4H, m), 6.94 (2H, bs), 7.38 (1H, d), 7.84 (1H, d),  
8.04 (2H, bs), 8.39 (1H, s), 9.22 (1H, s).

#### EXAMPLE 4

10        **6-Ethyl-8-[5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (61%) from the title compound of Preparation 4 and 1-methylpiperazine following the procedure of example 1.

m.p. 117 °C

15         $\delta$  (DMSO-d<sub>6</sub>): 1.01 (3H, t), 1.37 (3H, t), 1.86 (2H, m),  
2.38 (4H, m), 2.92 (4H, m), 4.26 (4H, m), 7.48 (1H, d),  
7.80 (1H, d), 8.21 (1H, s), 9.28 (1H, s), 13.72 (1H, bs)

#### EXAMPLE 5

20        **6-Ethyl-8-{2-propoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (86 %) from the title compound of Preparation 4 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 217 °C

25         $\delta$  (DMSO-d<sub>6</sub>): 1.0 (3H, t), 1.37 (3H, t), 1.89 (2H, m),  
30        2.36 (2H, t), 2.50 (2H, m), 2.79 (4H, m), 3.40 (2H, m),  
4.22 (2H, t), 4.38 (1H, bs), 7.48 (1H, d), 7.82 (1H, d),  
8.22 (1H, s), 9.28 (1H, s), 13.70 (1H, bs)

#### EXAMPLE 6

35        **6-Ethyl-8-(2-Butoxy-5-[4-(methylpiperazine-1-sulphonyl)phenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (56%) from the title compound of Preparation 6 and 1-methylpiperazine following the procedure of example 1.

m.p. 206 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.94 (3H, t), 1.38 (3H, t), 1.48 (2H, m), 1.84 (2H, m), 2.16 (3H, s), 2.38 (4H, m), 2.94 (4H, m), 4.31 (4H, m), 7.80 (1H, d), 7.81 (1H, d), 8.22 (1H, s), 9.26 (1H, s), 13.71 (1H, bs)

10        EXAMPLE 7

**4-Butoxy-3-(6-ethyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N,N-bis-(2-hydroxyethyl)benzenesulfonamide**

15        Obtained as a white solid (71%) from the title compound of Preparation 6 and diethanolamine following the procedure of example 1.

m.p. 189 °C

20         $\delta$  (DMSO-d<sub>6</sub>): 0.94 (3H, m), 1.39 (5H, m), 1.84 (2H, m), 3.23 (4H, m), 3.56 (4H, m), 4.29 (4H, m), 7.43 (1H, d), 7.89 (1H, d), 9.25 (1H, s).

EXAMPLE 8

25        **6-Ethyl-8-(2-butoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (54%) from the title compound of Preparation 6 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 235 °C

30         $\delta$  (DMSO-d<sub>6</sub>): 0.93 (3H, t), 1.37 (3H, t), 1.45 (2H, m), 1.86 (2H, m), 2.38 (2H, t), 2.50 (4H, m), 2.91 (4H, m), 3.42 (2H, m), 4.30 (5H, m), 7.48 (1H, d), 7.80 (1H, d), 8.20 (1H, s), 9.26 (1H, s), 13.72 (1H, bs)

35

EXAMPLE 9

**4-Butoxy-3-(6-ethyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(2-morpholin-4-ylethyl)benzenesulfonamide**

5        Obtained as a white solid (61%) from the title compound of Preparation 6 and N-(2-aminoethyl)morpholine following the procedure of example 1.

m.p. 158 °C

10         $\delta$  (DMSO-d<sub>6</sub>): 0.93 (3H, m), 1.41 (5H, m), 1.84 (2H, m),  
2.30 (6H, m), 2.90 (2H, m), 3.48 (4H, m), 4.30 (4H, m),  
7.43 (1H, d), 7.59 (1H, m), 7.88 (1H, d), 8.37 (1H, d),  
9.26 (1H, s).

EXAMPLE 10

15        **8-(2-Butoxy-5-{4-[2-(2-hydroxyethoxy)ethyl]piperazine-1-sulfonyl}phenyl)-6-ethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

20        Obtained as a white solid (70%) from the title compound of Preparation 6 and 1-[2-(2-hydroxyethoxy)ethyl]piperazine following the procedure of example 1.

m.p. 108 °C

25         $\delta$  (DMSO-d<sub>6</sub>): 0.94 (3H, m), 1.42 (5H, m), 1.83 (2H, m),  
2.46 (6H, m), 2.91 (4H, m), 3.36 (6H, m), 4.32 (4H, m),  
7.47 (1H, d), 7.78 (1H, d), 8.22 (1H, d), 9.27 (1H, s).

EXAMPLE 11

**8-{2-Ethoxy-5-[4-morpholine-1-sulphonyl]phenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

30        Obtained as a white solid (37%) from the title compound of Preparation 8 and morpholine following the procedure of example 1.

m.p. 265 °C

35         $\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.45 (3H, t), 1.85 (2H, m),  
2.90 (4H, m), 3.65 (4H, m), 4.20 (2H, t), 4.40 (2H, c),  
7.45 (1H, d), 7.80 (1H, d), 8.22 (1H, s), 9.25 (1H, s),  
13.7 (1H, bs)

EXAMPLE 12

**8-[2-Ethoxy-5-(4-methylpiperazine-1-sulphonyl)phenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (68%) from the title compound of Preparation 8 and 1-methylpiperazine following the procedure of example 1.

m.p. 252 °C

$\delta$  (DMSO-d<sub>6</sub>): 1.0 (3H, t), 1.48 (3H, t), 1.88 (2H, m), 2.19 (3H, s), 2.40 (4H, m), 2.94 (4H, m), 4.21 (2H, t), 4.41 (2H, q), 7.48 (1H, d), 7.82 (1H, d), 8.22 (1H, s), 9.28 (1H, s), 13.68 (1H, bs)

EXAMPLE 13

**8-{2-Ethoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (21%) from the title compound of Preparation 8 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 223 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.60 (3H, t), 1.85 (2H, m), 2.38 (2H, t), 2.50 (4H, m), 2.91 (4H, m), 3.41 (2H, m), 4.19 (2H, t), 2.39 (3H, m), 7.46 (1H, d), 7.81 (1H, d), 8.22 (1H, s), 9.28 (1H, s), 13.72 (1H, bs)

EXAMPLE 14

**8-[2-Ethoxy-5-(piperazine-1-sulphonyl)phenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (25%) from the title compound of Preparation 10 and piperazine following the procedure of example 1.

m.p. 230 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.97 (3H, t), 1.00 (3H, t), 1.86 (4H, m), 2.81 (8H, m), 4.19 (2H, t), 4.37 (2H, t), 7.46 (1H, d), 7.78 (1H, d), 8.19 (1H, s), 9.26 (1H, bs)

EXAMPLE 15

**8-[5-(morpholinosulphonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one**

A stirred mixture of the title compound of Preparation 22 (0.22 g, 0.45 mmol) and formic acid (5 mL) was heated under reflux for 2 hours. The resulting solution was concentrated under vacuum and the residue partitioned between dichloromethane and aqueous sodium bicarbonate solution, then the organic phase separated, washed with water, dried (MgSO<sub>4</sub>) and evaporated under reduced pressure to yield the crude product which was purified by Flash Column Chromatography (SiO<sub>2</sub>, dichloromethane-methanol 98:2) to give the title compound (0.17 g, 76%) as an off-white solid.

m.p. 169 °C

δ (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.02 (3H, t), 1.86 (4H, m), 2.89 (4H, m), 3.61 (4H, m), 4.20 (2H, t), 4.24 (2H, t), 7.45 (1H, d), 7.82 (1H, d), 8.22 (1H, s), 9.28 (1H, s), 13.68 (1H, s)

EXAMPLE 16

**N-(2-Dimethylaminoethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulphonamide**

Obtained as a white solid (36%) from the title compound of Preparation 10 and *N,N*-dimethylethylenediamine following the procedure of example 1.

LRMS: m/z 503 (M+1)<sup>+</sup>.

δ (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.02 (3H, t), 1.86 (4H, m), 2.89 (4H, m), 3.61 (4H, m), 4.20 (2H, t), 4.24 (2H, t), 7.45 (1H, d), 7.82 (1H, d), 8.22 (1H, s), 9.28 (1H, s), 13.68 (1H, s)

EXAMPLE 17

**3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxy-*N*-pyridin-4-yl-benzenesulphonamide**

Obtained as a white solid (10%) from the title compound of Preparation 10 and 4-aminopyridine following the procedure of example 1.

m.p. 265 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.02 (3H, t), 1.86 (4H, m),  
2.89 (4H, m), 3.61 (4H, m), 4.20 (2H, t), 4.24 (2H, t),  
7.45 (1H, d), 7.82 (1H, d), 8.22 (1H, s), 9.28 (1H, s),  
13.68 (1H, s)

10        EXAMPLE 18

**8-[5-(4-Methylpiperazinosulphonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (82%) from the title compound of Preparation 19 following the procedure of  
15        example 15.

m.p. 272 °C

20         $\delta$  (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.00 (3H, t), 1.83 (4H, m),  
2.18 (3H, s), 2.38 (4H, m), 2.86 (4H, m), 4.19 (2H, t),  
4.28 (2H, t), 7.44 (1H, d), 7.80 (1H, d), 8.19 (1H, s),  
9.23 (1H, s), 13.75 (1H, bs)

EXAMPLE 19

**8-[5-(4-Hydroxypiperidine-1-sulphonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

25        Obtained as a white solid (35%) from the title compound of Preparation 10 and 4-hydroxypiperidine following the procedure of example 1.

LRMS: m/z 516 (M+1)<sup>+</sup>.

30         $\delta$  (DMSO-d<sub>6</sub>): 0.98 (6H, m), 1.48 (2H, m), 1.74 (2H, m),  
1.84 (4H, m), 2.77 (2H, m), 3.16 (2H, m), 3.60 (1H, m),  
4.21 (1H, m), 4.68 (1H, s), 7.45 (1H, d), 7.78 (1H, d),  
8.20 (1H, s), 9.26 (1H, s), 13.8 (1H, bs)

EXAMPLE 20

35        **N,N-Bis-(2-hydroxyethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonamide**



Obtained as a white solid (28%) from the title compound of Preparation 10 and diethanolamine following the procedure of example 1.

LRMS: m/z 520 (M+1)<sup>+</sup>.

5           δ (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.86 (4H, m), 3.20 (4H, t),  
3.54 (4H, t), 4.20 (4H, m), 4.82 (2H, bs), 7.41 (1H, d),  
7.83 (1H, d), 8.31 (1H, s), 9.23 (1H, s), 12.0 (1H, bs)

#### EXAMPLE 21

10   **4-[3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl]piperazine-1-carbaldehyde**

Obtained as a white solid (28%) from the title compound of Preparation 20 following the procedure of  
15   example 15.

m.p. 232 °C

          δ (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.0 (3H, t), 1.86 (4H, m),  
2.93 (4H, m), 3.45 (4H, m), 4.20 (2H, t), 4.24 (2H, t),  
7.46 (1H, d), 7.80 (1H, d), 7.94 (1H, s), 8.20 (1H, s),  
20   9.26 (1H, s), 13.76 (1H, s)

#### EXAMPLE 22

**8-[5-(4-Methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**  
25

Obtained as a white solid (32%) from the title compound of Preparation 21 following the procedure of example 15.

m.p. 193 °C

30           δ (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.98 (3H, t), 1.8 (6H, m),  
2.22 (3H, s), 2.50 (2H, m), 2.58 (2H, m), 3.32 (4H, m),  
4.18 (2H, t), 4.26 (2H, t), 7.40 (1H, d), 7.83 (1H, d),  
8.22 (1H, s), 9.25 (1H, s)

#### 35   EXAMPLE 23

**8-[5-(4-Ethylpiperazine-1-sulphonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (48%) from the title compound of Preparation 10 and 1-ethylpiperazine following the procedure of example 1.

LRMS: m/z 529 (M+1)<sup>+</sup>.

5        δ (DMSO-d<sub>6</sub>): 0.97 (9H, m), 1.83 (4H, m), 2.36 (2H, m),  
2.45 (2H, m), 2.94 (4H, m), 3.35 (2H, m), 4.19 (2H, t),  
4.27 (2H, t), 7.47 (1H, d), 7.80 (1H, d), 8.19 (1H, s),  
9.26 (1H, s)

10        EXAMPLE 24

**1-[3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl]piperidine-4-carboxylic acid amide**

15        Obtained as a white solid (12%) from the title compound of Preparation 10 and isonipecotamide following the procedure of example 1.

m.p. 272 °C

20        δ (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.98 (3H, t), 1.58 (2H, m),  
1.6-1.8 (6H, m), 2.07 (1H, m), 2.36 (2H, m), 3.57 (2H, m),  
4.19 (2H, t), 4.28 (2H, t), 6.81 (1H, s), 7.20 (1H, s),  
7.46 (1H, d), 7.82 (1H, d), 8.20 (1H, s), 9.27 (1H, s),  
13.72 (1H, s)

EXAMPLE 25

25        **1-[3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulphonyl]piperidine-3-carboxylic acid amide**

30        Obtained as a white solid (55%) from the title compound of Preparation 10 and nipecotamide following the procedure of example 1.

LRMS: m/z 543 (M+1)<sup>+</sup>.

35        δ (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.21 (1H, m), 1.50 (1H, m),  
1.82 (6H, m), 2.26 (2H, m), 2.40 (1H, m), 3.62 (2H, m),  
4.18 (2H, t), 4.27 (2H, t), 6.95 (1H, s), 7.42 (1H, s),  
7.46 (1H, d), 7.80 (1H, d), 8.20 (1H, s), 9.25 (1H, s),  
13.75 (1H, s)

EXAMPLE 26

**3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-  
i]purin-8-yl)-N-(2-piperidin-1-ylethyl)-4-propoxy  
benzenesulphonamide**

5            Obtained as a white solid (45%) from the title  
compound of Preparation 10 and 1-(2-aminoethyl)piperidine  
following the procedure of example 1.

LRMS: m/z 543 (M+1)<sup>+</sup>.

10            δ (DMSO-d<sub>6</sub>): 9.26 (1H, s), 8.32 (1H, s), 7.83 (1H, d),  
7.62 (1H, s), 7.43 (1H, d), 4.21 (4H, m), 2.92 (2H, m),  
2.41 (6H, m), 1.86 (4H, m), 1.46 (4H, m), 1.38 (2H, m),  
0.97 (6H, m)

EXAMPLE 27

15            **8-{5-[4-(2-Hydroxyethyl)piperazine-1-sulphonyl]-2-  
propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-  
i]purin-5-one**

20            Obtained as a white solid (41%) from the title  
compound of Preparation 10 and 1-(2-  
hydroxyethyl)piperazine following the procedure of example  
1.

m.p. 194 °C

25            δ (DMSO-d<sub>6</sub>): 0.95 (3H, t), 0.99 (3H, t), 1.84 (4H, m),  
2.36 (2H, m), 2.50 (4H, m), 2.82 (4H, m), 3.40 (2H, m),  
4.18 (2H, t), 4.28 (2H, t), 4.37 (1H, bs), 7.46 (1H, d),  
7.80 (1H, d), 8.18 (1H, s), 9.26 (1H, s), 13.76 (1H, bs)

EXAMPLE 28

30            **N-(2-Morpholin-4-yl-ethyl)-3-(5-oxo-6-propyl-6,9-dihydro-  
5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzene  
sulphonamide**

35            Obtained as a white solid (40%) from the title  
compound of Preparation 10 and 4-(2-aminoethyl)morpholine  
following the procedure of example 1.

LRMS: m/z 545 (M+1)<sup>+</sup>.

δ (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.85 (4H, m), 2.28 (6H, m),  
2.90 (2H, m), 3.48 (4H, m), 4.23 (4H, m), 7.43 (1H, d),

7.62 (1H, s), 7.90 (1H, d), 8.32 (1H, s), 9.26 (1H, s),  
13.60 (1H, bs)

EXAMPLE 29

5 ***N*-(3-Morpholin-4-yl-propyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzene sulphonamide**

Obtained as a white solid (29%) from the title compound of Preparation 10 and 4-(3-aminopropyl)morpholine following the procedure of example 1.

LRMS: m/z 559 (M+1)<sup>+</sup>.

δ (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.86 (4H, m), 2.30 (6H, m),  
2.81 (2H, m), 3.51 (4H, m), 4.23 (4H, m), 7.43 (1H, d),  
7.63 (1H, s), 7.85 (1H, d), 8.31 (1H, s), 9.25 (1H, s)

EXAMPLE 30

8-(5-{4-[2-(2-Hydroxyethoxy)ethyl]piperazine-1-sulphonyl}-2-propoxyphenyl)-6-propyl-6,9-dihydro-[1,2,4]triazolo  
[3,4-*i*]purin-5-one

Obtained as a white solid (60%) from the title compound of Preparation 10 and 1-[2-(2-hydroxyethoxy)ethyl]piperazine following the procedure of example 1.

m.p. 116 °C

δ (DMSO-d<sub>6</sub>): 1.03 (6H, m), 1.84 (4H, m), 2.45 (6H, m),  
2.92 (4H, m), 3.39 (6H, m), 4.21 (4H, m), 4.58 (1H, s),  
7.41 (1H, d).

EXAMPLE 31

30 **8-[2-Butoxy-5-(morpholine-4-sulphonyl)phenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one**

Obtained as a white solid (39%) from the title compound of Preparation 23 following the procedure of example 15.

35 m.p. 208 °C

δ (DMSO-d<sub>6</sub>): 0.94 (3H, t), 0.96 (3H, t), 1.48 (2H, m),  
1.84 (4H, m) 2.93 (4H, m), 3.64 (4H, m), 4.20 (2H, t), 4.31

(2H, t), 7.48 (1H, d), 7.82 (1H, d), 8.20 (1H, s), 9.26 (1H, s), 13.76 (1H, s)

EXAMPLE 32

5 **8-[5-(2-butoxy-4-methylpiperazinosulphonyl)phenyl]-6-propyl-6,9-dihydro-1,2,4-triazolo[3,4-i]purin-5-one**

Obtained as a white solid (17%) from the title compound of Preparation 24 following the procedure of example 15.

10 m.p. 208 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.91 (3H, t), 0.92 (3H, t), 1.43 (2H, m), 1.81 (4H, m), 2.09 (3H, s), 2.36 (4H, m), 2.88 (4H, m), 4.17 (2H, t), 4.26 (2H, t), 7.44 (1H, d), 7.79 (1H, d), 8.17 (1H, s), 9.25 (1H, s)

15

EXAMPLE 33

**6-Butyl-8-[2-ethoxy-5-(4-methylpiperazine-1-sulphonyl)phenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

20 Obtained as a white solid (72%) from the title compound of Preparation 12 and 1-methylpiperazine following the procedure of example 1.

m.p. 238 °C

25  $\delta$  (DMSO-d<sub>6</sub>): 0.99 (3H, t), 1.42 (5H, m), 1.82 (2H, m), 2.16 (3H, s), 2.40 (4H, m), 2.92 (4H, m), 4.22 (2H, t), 4.40 (2H, q), 7.44 (1H, d), 7.80 (1H, d), 8.22 (1H, s), 9.24 (1H, s), 13.48 (1H, s)

EXAMPLE 34

30 **6-Butyl-8-{2-ethoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (45%) from the title compound of Preparation 12 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

35

m.p. 241 °C



5  
10057847-013502  
20250724 14:00T  
 $\delta$  (DMSO-d<sub>6</sub>): 0.83 (6H, m), 1.36 (2H, m), 1.80 (4H, m),  
2.12 (3H, s), 2.38 (4H, m), 2.92 (4H, m), 4.23 (4H, m),  
7.45 (1H, d), 7.79 (1H, d), 8.19 (1H, s), 9.21 (1H, s),  
13.69 (1H, bs).

EXAMPLE 38

**6-Butyl-8-[5-(4-hydroxypiperidine-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

10        Obtained as a white solid (70%) from the title compound of Preparation 14 and 4-hydroxypiperidine following the procedure of example 1.

m.p. 262 °C

15         $\delta$  (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.41 (4H, m), 1.81 (6H, m),  
2.78 (2H, m), 3.16 (2H, m), 3.55 (1H, bs), 4.24 (4H, m),  
4.67 (1H, d), 7.45 (1H, d), 7.80 (1H, d), 8.23 (1H, d),  
9.25 (1H, s).

EXAMPLE 39

20        **3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N,N-bis-(2-hydroxyethyl)-4-propoxybenzenesulfonamide**

25        Obtained as a white solid (50%) from the title compound of Preparation 14 and diethanolamine following the procedure of example 1.

m.p. 202 °C

30         $\delta$  (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.38 (2H, m), 1.82 (4H, m),  
3.19 (4H, m), 3.54 (4H, m), 4.25 (4H, m), 4.84 (2H, m),  
7.42 (1H, d), 7.87 (1H, d), 8.29 (1H, d), 9.25 (1H, s),  
13.69 (1H, s).

EXAMPLE 40

35        **6-Butyl-8-[5-(4-methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (39%) from the title compound of Preparation 14 and 1-methylhomopiperazine following the procedure of example 1.

m.p. 282 °C

5        d (CDCl<sub>3</sub>): 1.03 (3H, t), 1.14 (3H, t), 1.47 (2H, m),  
1.8-2.2 (6H, m), 2.38 (3H, s), 2.68 (4H, m), 3.46 (4H, m),  
4.38 (4H, m), 7.19 (1H, d), 7.86 (1H, d), 8.79 (1H, s),  
8.96 (1H, s).

10        EXAMPLE 41

**6-Butyl-8-{2-propoxy-5-[4-(ethylpiperazine-1-sulphonyl)phenyl]-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-one**

15        Obtained as a white solid (61%) from the title compound of Preparation 14 and 1-ethylpiperazine following the procedure of example 1.

m.p. 208 °C

20        d (CDCl<sub>3</sub>): 0.98 (6H, m), 1.16 (3H, t), 1.48 (2H, m),  
1.91 (2H, m), 2.04 (2H, m), 2.42 (2H, q), 2.54 (4H, m),  
3.13 (4H, m), 4.37 (4H, m), 7.09 (1H, d), 7.82 (1H, d),  
8.77 (1H, s), 8.97 (1H, s).

EXAMPLE 42

25        **3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(2-piperidin-1-ylethyl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (60%) from the title compound of Preparation 14 and 1-(2-aminoethyl)piperidine following the procedure of example 1.

30        m.p. 186 °C

δ (DMSO-d<sub>6</sub>): 0.96 (6H, m), 1.33 (8H, m), 1.83 (4H, m),  
2.28 (6H, m), 2.87 (2H, m), 4.24 (4H, m), 7.41 (1H, d),  
7.51 (1H, m), 7.85 (1H, d), 8.33 (1H, d), 9.23 (1H, s).

35



EXAMPLE 43

**6-Butyl-8-(2-propoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5- one**

5            Obtained as a white solid (81%) from the title compound of Preparation 14 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 242 °C

10             $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 1.0 (3H, t), 1.38 (2H, m), 1.86 (4H, m), 2.37 (2H, t), 2.50 (4H, m), 2.92 (4H, m), 3.43 (2H, m), 4.26 (4H, m), 4.37 (1H, bs), 7.47 (1H, d), 7.80 (1H, d), 8.21 (1H, s), 9.25 (1H, s), 13.70 (1H, bs).

15            EXAMPLE 44

**3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(2-morpholin-4-ylethyl)-4-propoxybenzenesulfonamide**

20            Obtained as a white solid (72%) from the title compound of Preparation 14 and 4-(2-aminoethyl)morpholine following the procedure of example 1.

m.p. 192 °C

25             $\delta$  (DMSO-d<sub>6</sub>): 0.95 (6H, m), 1.38 (2H, m), 1.83 (4H, m), 2.28 (6H, m), 2.90 (2H, m), 3.46 (4H, m), 4.25 (4H, m), 7.42 (1H, d), 7.59 (1H, m), 7.87 (1H, d), 8.33 (1H, d), 9.25 (1H, s).

EXAMPLE 45

30            **3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(3-morpholin-4-ylpropyl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (65%) from the title compound of Preparation 14 and 4-(3-aminopropyl)morpholine following the procedure of example 1.

35            m.p. 174 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.96 (6H, m), 1.38 (2H, m), 1.52 (2H, m), 1.84 (4H, m), 2.21 (6H, m), 2.81 (2H, m), 3.47 (4H, m),

4.25 (4H, m), 7.43 (1H, d), 7.63 (1H, m), 7.84 (1H, d),  
8.32 (1H, d), 9.25 (1H, s).

EXAMPLE 46

5 **3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-  
i]purin-8-yl)-N-methyl-N-(2-morpholin-4-ylethyl)-4-  
propoxybenzenesulfonamide**

Obtained as a white solid (65%) from the title  
compound of Preparation 14 and 4-(3-aminopropyl)morpholine  
10 following the procedure of example 1.

m.p. 170 °C

δ (DMSO-d6): 0.97 (6H, m), 1.38 (2H, m), 1.82 (4H, m),  
2.46 (6H, m), 2.76 (3H, s), 3.12 (2H, m), 3.51 (4H, m),  
4.24 (4H, m), 7.43 (1H, d), 7.84 (1H, d), 8.26 (1H, d),  
15 9.25 (1H, s).

EXAMPLE 47

**6-Butyl-8-(5-{4-[2-(2-hydroxyethoxy)ethyl]piperazine-1-  
sulfonyl}-2-propoxyphenyl)-6,9-dihydro-  
20 [1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (64%) from the title  
compound of Preparation 14 and 1-[2-(2-  
hydroxyethoxy)ethyl]piperazine following the procedure of  
example 1.

25 m.p. 143 °C

δ (DMSO-d6): 0.83 (6H, m), 1.27 (2H, m), 1.68 (4H, m),  
2.35 (6H, m), 2.75 (4H, m), 3.23 (6H, m), 4.11 (4H, m),  
7.31 (1H, d), 7.63 (1H, d), 8.06 (1H, s), 9.10 (1H, s).

30 EXAMPLE 48

**6-Butyl-8-(2-butoxy-5-[4-(methylpiperazine-1-  
sulphonyl)phenyl]-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-  
5- one**

Obtained as a white solid (62%) from the title  
35 compound of Preparation 16 and 1-methylpiperazine  
following the procedure of example 1.

m.p. 201 °C

10057847-01303  
206210-4484001  
 $\delta$  (DMSO-d<sub>6</sub>): 0.98 (6H, m), 1.4 (4H, m), 1.8 (4H, m),  
2.19 (3H, s), 2.4 (4H, m), 2.90 (4H, m), 4.25 (2H, t),  
4.30 (2H, t), 7.45 (1H, d), 7.79 (1H, d), 8.20 (1H, s),  
9.25 (1H, s), 13.65 (1H, bs)

5

EXAMPLE 49

**6-Butyl-8-(2-butoxy-5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]phenyl}-6,9-dihydro[1,2,4]triazolo[3,4-i]purin-5-one**

10        Obtained as a white solid (66%) from the title compound of Preparation 16 and 1-methylpiperazine following the procedure of example 1.

m.p. 218 °C

15         $\delta$  (DMSO-d<sub>6</sub>): 0.95 (6H, m), 1.20 (4H, m), 1.85 (4H, m),  
2.40 (2H, t), 2.51 (4H, m), 2.92 (4H, m), 3.40 (2H, m),  
4.25 (5H, m), 7.48 (1H, d), 7.80 (1H, d), 8.24 (1H, s),  
9.28 (1H, s), 13.65 (1H, bs).

EXAMPLE 50

20        **8-[5-(4-Methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-pyridin-2-ylmethyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

25        Obtained as a white solid (82%) from the title compound of Preparation 26 and 1-methylpiperazine following the procedure of example 1.

m.p. 227 °C

30         $\delta$  (DMSO-d<sub>6</sub>): 0.93 (3H, m), 1.80 (2H, m), 2.13 (3H, s),  
2.35 (4H, m), 2.87 (4H, m), 4.24 (2H, m), 5.53 (2H, m),  
7.28 (1H, m), 7.44 (2H, m), 7.75 (2H, m), 8.09 (1H, d),  
8.45 (1H, d), 9.31 (1H, s).

EXAMPLE 51

35        **8-[5-(N,N-Dimethylaminosulphonyl)-2-propoxyphenyl]-3-methyl-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-2,6-dione**

Obtained as a white solid (65%) from the title compound of Preparation 18 and dimethylamine following the procedure of example 1.

m.p. 226 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.98 (3H, t), 1.84 (4H, m),  
2.62 (6H, s), 2.78 (3H, s), 4.16 (2H, t), 4.24 (2H, t),  
7.44 (1H, d), 7.81 (1H, d), 8.21 (1H, s), 13.59 (1H, s)

#### EXAMPLE 52

10        **3-Methyl-8-[5-(4-methylpiperazine-1-sulphonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (62%) from the title compound of Preparation 18 and 1-methylpiperazine following the procedure of example 1.

m.p. 226 °C

15         $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.99 (3H, t), 1.82 (4H, m),  
2.16 (3H, s), 2.37 (4H, m), 2.78 (3H, s), 2.84 (4H, m),  
4.14 (2H, t), 4.28 (2H, t), 7.44 (1H, d), 7.78 (1H, d),  
20        8.19 (1H, s), 13.60 (1H, s)

#### EXAMPLE 53

25        **8-{5-[4-(2-hydroxyethyl)piperazine-1-sulphonyl]-2-propoxyphenyl}-3-methyl-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (61%) from the title compound of Preparation 18 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

30        m.p. 199 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.92 (3H, t), 0.98 (3H, t), 1.82 (4H, m),  
2.38 (2H, t), 2.46 (4H, m), 2.77 (3H, s), 2.84 (4H, m),  
3.39 (2H, m), 4.16 (2H, t), 4.24 (2H, t), 4.37 (1H, t),  
7.43 (1H, d), 7.79 (1H, d), 8.18 (1H, s), 13.60 (1H, s)

35

EXAMPLE 54

6-Butyl-8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-3-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

5            Obtained as a cream solid (77%) from the title compound of Preparation 28 and 1-methylpiperazine following the procedure of example 1.

m.p. 206 °C

10             $\delta$  (DMSO-d<sub>6</sub>): 0.97 (9H, m), 1.37 (2H, m), 1.81 (6H, m), 2.14 (3H, s), 2.37 (4H, m), 2.92 (4H, m), 3.19 (2H, m), 4.17 (2H, m), 4.26 (2H, m), 7.45 (1H, d), 7.79 (1H, d), 8.19 (1H, d), 13.59 (1H, bs).

EXAMPLE 55

15            6-Butyl-8-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-3-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

20            Obtained as a pale yellow solid (83%) from the title compound of Preparation 28 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

m.p. 193 °C

25             $\delta$  (DMSO-d<sub>6</sub>): 0.97 (9H, m), 1.37 (2H, m), 1.81 (6H, m), 2.14 (3H, s), 2.37 (4H, m), 2.92 (4H, m), 3.19 (2H, m), 4.17 (2H, m), 4.26 (2H, m), 7.45 (1H, d), 7.79 (1H, d), 8.19 (1H, d), 13.59 (1H, bs).

EXAMPLE 56

30            6-Butyl-8-(5-{4-[2-(2-hydroxyethoxy)ethyl]piperazine-1-sulfonyl}-2-propoxyphenyl)-3-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

35            Obtained as a pale yellow solid (81%) from the title compound of Preparation 28 and 1-[2-(2-hydroxyethoxy)ethyl]piperazine following the procedure of example 1.

m.p. 144 °C

δ (DMSO-d6): 0.97 (9H, m), 1.38 (2H, m), 1.81 (6H, m),  
2.46 (6H, m), 2.91 (4H, m), 3.19 (2H, m), 3.37 (6H, m),  
4.18 (2H, m), 4.27 (2H, m), 7.45 (1H, d), 7.80 (1H, d),  
8.19 (1H, d).

5

EXAMPLE 57

**3-Benzyl-8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

10 To a mixture of the title compound of Preparation 19  
(0.5 g, 1.0 mmol) and triethylamine (0.2 mL, 1.3 mmol) in  
dichloromethane (40 mL) was added phenylacetyl chloride  
(0.17 mL, 1.3 mmol) and the resulting mixture was stirred  
15 at room temperature for 24 hours, then evaporated under  
reduced pressure. Toluene (40 mL) and a catalytic amount  
of p-toluenesulphonic acid was added to the residue and  
the resulting mixture refluxed for 2 hours using a Dean-  
Stark apparatus, then evaporated under reduced pressure to  
20 yield the crude product which was purified by Flash Column  
Chromatography (SiO<sub>2</sub>, dichloromethane-ethanol-aq. ammonia  
100:4:0.5) to yield the title compound (0.11 g, 18%) as a  
white solid.

m.p. 202 °C

25 δ (DMSO-d6): 0.92 (3H, t), 0.96 (3H, t), 1.81 (4H, m),  
2.14 (3H, s), 2.37 (4H, m), 2.92 (4H, m), 4.12 (2H, t),  
4.25 (2H, t), 4.65 (2H, s), 7.30 (5H, m), 7.45 (1H, d),  
7.77 (1H, d), 8.17 (1H, s).

EXAMPLE 58

30 **6-Isobutyl-8-[5-(4-methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (51%) from the title  
compound of Preparation 30 and 1-methylpiperazine  
35 following the procedure of example 1.

LRMS: m/z 528 (M+1)+.



Obtained as a white solid (29%) from the title compound of Preparation 30 and 4-(3-aminopropyl)morpholine following the procedure of example 1.

LRMS: m/z 572 (M+1)+.

5         $\delta$  (DMSO-d6): 1.09 (9H, m), 1.59 (2H, m), 1.85 (2H, m),  
2.40 (6H, m), 2.81 (2H, m), 3.37 (4H, m), 4.06 (2H, d),  
4.26 (2H, t), 7.43 (1H, d), 7.70 (1H, t), 7.85 (1H, dd),  
8.30 (1H, d), 9.26 (1H, s), 13.5 (1H, bs).

10        EXAMPLE 62

**8-[5-(4-Ethylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-isobutyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (52%) from the title compound of Preparation 30 and 1-ethylpiperazine following the procedure of example 1.

LRMS: m/z 542 (M+1)+.

15         $\delta$  (DMSO-d6): 1.00 (12H, m), 1.86 (2H, m), 2.45 (7H,  
m), 2.97 (4H, m), 4.05 (2H, d), 4.27 (2H, t), 7.47 (1H,  
d), 7.81 (1H, dd), 8.20 (1H, d), 9.27 (1H, s), 13.7 (1H,  
20        bs).

EXAMPLE 63

**8-{5-[4-(2-Hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-isobutyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

25        Obtained as a white solid (42%) from the title compound of Preparation 30 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

30        LRMS: m/z 558 (M+1)+.

$\delta$  (DMSO-d6): 1.00 (9H, m), 1.86 (2H, m), 2.36 (1H, m),  
2.64 (4H, m), 2.99 (4H, m), 3.35 (4H, m), 4.05 (2H, d),  
4.27 (2H, t), 4.56 (1H, bs), 7.47 (1H, d), 7.81 (1H, dd),  
8.19 (1H, d), 9.27 (1H, s), 13.8 (1H, bs).

35



EXAMPLE 64

**8-[5-(4-Hydroxypiperidine-1-sulfonyl)-2-propoxyphenyl]-6-isobutyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (53%) from the title compound of Preparation 30 and 4-hydroxypiperidine following the procedure of example 1.

LRMS: m/z 529 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.95 (9H, m), 1.45 (2H, m), 1.79 (4H, m), 2.36 (1H, m), 2.77 (2H, m), 3.17 (2H, m), 3.55 (1H, m), 4.04 (2H, d), 4.26 (2H, t), 4.69 (1H, d), 7.45 (1H, d), 7.80 (1H, dd), 8.20 (1H, d), 9.26 (1H, s), 13.76 (1H, s).

EXAMPLE 65

**3-(6-Isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(2-piperidin-1-ylethyl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (60%) from the title compound of Preparation 30 and 1-(2-aminoethyl)piperidine following the procedure of example 1.

LRMS: m/z 556 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 1.00 (9H, m), 1.41 (2H, m), 1.55 (4H, m), 1.87 (2H, m), 2.38 (1H, m), 2.65 (4H, m), 3.03 (4H, m), 4.06 (2H, d), 4.27 (2H, t), 7.44 (1H, d), 7.89 (1H, dd), 7.82 (1H, bs), 8.31 (1H, d), 9.26 (1H, s).

EXAMPLE 66

**N-(2-Dimethylaminoethyl)-3-(6-isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (43%) from the title compound of Preparation 30 and N,N'-dimethylethylenediamine following the procedure of example 1.

LRMS: m/z 516 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.95 (9H, m), 1.84 (2H, m), 2.33 (1H, m), 2.33 (6H, s), 2.61 (2H, m), 2.94 (2H, m), 4.03 (2H, d),

4.23 (2H, t), 7.41 (1H, d), 7.82 (1H, bs), 7.86 (1H, dd),  
8.28 (1H, d), 9.23 (1H, s).

EXAMPLE 67

5 **6-Isobutyl-8-[5-(morpholinosulphonyl)-2-propoxyphenyl]-  
6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (53%) from the title  
compound of Preparation 30 and morpholine following the  
procedure of example 1.

10 LRMS: m/z 515 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.96 (9H, m), 1.83 (2H, m), 2.33 (1H, m),  
2.88 (4H, m), 3.62 (4H, m), 4.02 (2H, d), 4.24 (2H, t),  
7.45 (1H, d), 7.78 (1H, d), 8.16 (1H, s), 9.23 (1H, s),  
13.77 (1H, s).

15

EXAMPLE 68

**3-(6-Isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-  
i]purin-8-yl)-N-methyl-N-(2-morpholin-4-ylethyl)-4-  
propoxybenzenesulfonamide**

20 Obtained as a white solid (53%) from the title  
compound of Preparation 30 and 4-[2-(N-  
methylamino)ethyl]morpholine following the procedure of  
example 1.

LRMS: m/z 572 (M+1)+.

25  $\delta$  (DMSO-d<sub>6</sub>): 0.94 (9H, m), 1.84 (2H, m), 2.41 (6H, m),  
2.74 (3H, s), 3.11 (2H, m), 3.52 (4H, m), 4.01 (2H, d),  
4.23 (2H, t), 7.41 (1H, d), 7.83 (1H, d), 8.22 (1H, s),  
9.23 (1H, s).

30 EXAMPLE 69

**8-[5-(4-Methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-  
pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (35%) from the title  
compound of Preparation 32 and 1-methylpiperazine  
35 following the procedure of example 1.

LRMS: m/z 542 (M+1)+.

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995

$\delta$  (DMSO-d<sub>6</sub>): 0.85 (3H, t), 0.97 (3H, t), 1.33 (4H, m),  
1.83 (4H, m), 2.25 (3H, s), 2.48 (4H, m), 2.96 (4H, m),  
4.22 (4H, m), 7.45 (1H, d), 7.78 (1H, d), 8.20 (1H, s),  
9.24 (1H, s), 13.7 (1H, bs).

EXAMPLE 70

**8-[5-(4-Methyl-[1,4]diazepane-1-sulfonyl)-2-propoxyphenyl]-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (40%) from the title compound of Preparation 32 and 1-methylhomopiperazine following the procedure of example 1.

LRMS: m/z 556 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.89 (3H, t), 1.02 (3H, t), 1.37 (4H, m),  
1.85 (7H, m), 2.50 (2H, m), 2.98 (4H, m), 3.32 (4H, m),  
4.23 (4H, m), 7.44 (1H, d), 7.86 (1H, dd), 8.27 (1H, d),  
9.26 (1H, s).

EXAMPLE 71

**N-(2-Morpholin-4-ylethyl)-3-(5-oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzene sulfonamide**

Obtained as a white solid (32%) from the title compound of Preparation 32 and 4-(2-aminoethyl)morpholine following the procedure of example 1.

LRMS: m/z 572 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.90 (3H, t), 0.98 (3H, t), 1.36 (4H, m),  
1.86 (4H, m), 2.41 (6H, m), 2.94 (2H, m), 3.53 (4H, m),  
4.25 (4H, m), 7.43 (1H, d), 7.68 (1H, bs), 7.88 (1H, dd),  
8.33 (1H, d), 8.26 (1H, s), 13.65 (1H, bs).

EXAMPLE 72

**N-(3-Morpholin-4-ylpropyl)-3-(5-oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzene sulfonamide**

Obtained as a white solid (38%) from the title compound of Preparation 32 and 4-(3-aminopropyl)morpholine following the procedure of example 1.

LRMS: m/z 586 (M+1)+.

5         $\delta$  (DMSO-d<sub>6</sub>): 0.87 (3H, t), 0.95 (3H, t), 1.37 (4H, m),  
1.61 (2H, m), 1.85 (4H, m), 2.44 (6H, m), 2.81 (2H, m),  
3.38 (4H, m), 4.25 (4H, m), 7.44 (1H, d), 7.69 (1H, bs),  
7.85 (1H, dd), 8.32 (1H, d), 9.26 (1H, s), 13.6 (1H, bs).

10        EXAMPLE 73

**8-[5-(4-Ethylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (35%) from the title compound of Preparation 32 and 1-ethylpiperazine following the procedure of example 1.

15        LRMS: m/z 556 (M+1)+.

20         $\delta$  (DMSO-d<sub>6</sub>): 0.90 (3H, t), 1.00 (6H, m), 1.38 (4H, m),  
1.85 (4H, m), 2.49-3.07 (10H, m), 4.22 (2H, t), 4.29 (2H, t),  
7.48 (1H, d), 7.81 (1H, dd), 8.23 (1H, d), 9.27 (1H, s),  
13.75 (1H, bs).

EXAMPLE 74

**8-{5-[4-(2-Hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (33%) from the title compound of Preparation 32 and 1-(2-hydroxyethyl)piperazine following the procedure of example 1.

30        LRMS: m/z 572 (M+1)+.

35         $\delta$  (DMSO-d<sub>6</sub>): 0.88 (3H, t), 1.00 (3H, t), 1.36 (4H, m),  
1.88 (4H, m), 2.46 (4H, m), 2.70 (4H, m), 3.36 (4H, m),  
4.28 (4H, m), 4.46 (1H, bs), 7.48 (1H, d), 7.80 (1H, d),  
8.22 (1H, s), 9.27 (1H, s), 13.8 (1H, bs).

EXAMPLE 75

**8-[5-(4-Hydroxypiperidine-1-sulfonyl)-2-propoxyphenyl]-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (53%) from the title compound of Preparation 32 and 4-hydroxypiperidine following the procedure of example 1.

LRMS: m/z 543 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.88 (3H, t), 1.00 (6H, m), 1.42 (6H, m), 1.82 (6H, m), 2.77 (2H, m), 3.17 (2H, m), 3.54 (1H, m), 4.26 (4H, m), 4.69 (1H, s), 7.46 (1H, d), 7.80 (1H, dd), 8.23 (1H, d), 9.26 (1H, s), 13.7 (1H, s).

EXAMPLE 76

**3-(5-Oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-(2-piperidin-1-ylethyl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (55%) from the title compound of Preparation 32 and 1-(2-aminoethyl)piperidine following the procedure of example 1.

LRMS: m/z 579 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.88 (3H, t), 0.98 (3H, t), 1.37 (6H, m), 1.60 (4H, m), 1.85 (4H, m), 2.60-3.43 (8H, m), 4.25 (4H, m), 7.45 (1H, d), 7.89 (1H, dd), 7.82 (1H, bs), 8.33 (1H, d), 9.26 (1H, s).

EXAMPLE 77

**N-(2-Dimethylaminoethyl)-3-(5-oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (38%) from the title compound of Preparation 32 and N,N'-dimethylethylenediamine following the procedure of example 1.

LRMS: m/z 530 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.88 (3H, t), 0.99 (4H, m), 1.35 (4H, m), 1.85 (4H, m), 2.44 (1H, m), 2.44 (6H, s), 2.74 (2H, m),

2.99 (2H, m), 4.22 (4H, m), 7.45 (1H, d), 7.89 (1H, dd),  
8.34 (1H, d), 9.26 (1H, s).

EXAMPLE 78

5 **8-[5-(Morpholinosulphonyl)-2-propoxyphenyl]-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (30%) from the title compound of Preparation 32 and morpholine following the procedure of example 1.

10 LRMS: m/z 529 (M+1)+.

$\delta$  (DMSO-d<sub>6</sub>): 0.90 (3H, t), 0.99 (3H, t), 1.37 (4H, m),  
1.84 (4H, m), 2.89 (4H, m), 3.64 (4H, m), 4.22 (2H, t),  
4.29 (2H, t), 7.49 (1H, d), 7.81 (1H, d), 8.22 (1H, s),  
9.26 (1H, s), 13.75 (1H, bs).

15

EXAMPLE 79

**8-[2-Ethoxy-5-(piperazine-1-sulfonyl)phenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (45%) from the title compound of Preparation 4 and piperazine following the procedure of example 1.

20

m.p. 196 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.45 (3H, t), 1.84 (2H, m),  
2.76 (4H, m), 2.82 (4H, m), 4.19 (2H, t), 4.40 (2H, t),  
25 7.45 (1H, d), 7.77 (1H, d), 8.21 (1H, s), 9.24 (1H, s).

EXAMPLE 80

**3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide**

30 Obtained as a white solid (26%) from the title compound of Preparation 10 and ammonia following the procedure of example 1.

m.p. 275 °C

35  $\delta$  (DMSO-d<sub>6</sub>): 0.96 (6H, m), 1.85 (4H, m), 4.19 (t, 2H),  
4.26 (2H, t), 7.40 (2H, s), 7.41 (1H, d), 7.87 (1H, d),  
8.36 (1H, s), 9.26 (1H, s), 13.6 (1H, s).

EXAMPLE 81

3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-prop-2-ynylbenzenesulfonamide

Obtained as a white solid (41%) from the title compound of Preparation 10 and propargylamine following the procedure of example 1.

m.p. 251 °C

δ (DMSO-d<sub>6</sub>): 0.97 (6H, m), 1.85 (4H, m), 3.06 (1H, s), (3.71 (2H, s), 4.23 (4H, m), 7.42 (1H, d), 7.87 (1H, d), 8.33 (1H, s), 9.26 (1H, s), 13.6 (1H, s).

EXAMPLE 82

N-(2-Dimethylaminoethyl)-3-(oxopropyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide

Obtained as a white solid (45%) from the title compound of Preparation 10 and N,N-dimethylethylenediamine following the procedure of example 1.

m.p. 193 °C

δ (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.99 (3H, t), 1.86 (4H, m), 2.08 (6H, s), 2.29 (2H, t), 2.86 (2H, m), 4.20 (2H, t), 4.27 (2H, t), 7.42 (1H, d), 7.59 (1H, bs), 7.86 (1H, d), 8.32 (1H, s), 9.25 (1H, s).

EXAMPLE 83

8-{5-[(1S,4S)-(2,5-Diazabicyclo[2.2.1]hept-2-yl)sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

Obtained as a white solid (22%) from the title compound of Preparation 10 and tert-butyl (1S,4S)-(-)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate following the procedure of example 1 and further deprotection in a 1:1 mixture of trifluoroacetic acid and dichloromethane.

m.p. 153 °C

δ (DMSO-d<sub>6</sub>): 0.98 (7H, m), 1.40 (1H, d), 1.85 (4H, m), 2.83 (1H, d), 2.88 (1H, d), 3.11 (1H, d), 3.19 (1H, d),

3.63 (1H, d), 4.22 (4H, m), 4.34 (1H, s), 4.92 (1H, bs),  
7.39 (1H, d), 7.85 (1H, d), 8.29 (1H, s), 9.19 (1H, s).

EXAMPLE 84

5 **8-[5-([1,4]Diazepane-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (59%) from the title compound of Preparation 10 and homopiperazine following the procedure of example 1.

10 m.p. 208 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.02 (3H, t), 1.72 (2H, m),  
1.85 (4H, m), 2.80 (2H, t), 2.85 (2H, t), 3.27 (4H, m),  
4.20 (4H, m), 7.38 (1H, d), 7.79 (1H, d), 8.27 (1H, s),  
9.20 (1H, s).

15

EXAMPLE 85

**8-[5-((R)-3-Methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (80%) from the title compound of Preparation 10 and (R)-(-)-2-methylpiperazine following the procedure of example 1.

m.p. 156 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.93 (3H, d), 0.98 (3H, t), 1.00 (3H, t),  
1.83 (4H, m), 2.15 (1H, m), 2.70 (2H, m), 2.90 (1H, m),  
25 3.41 (4H, m), 4.18 (2H, t), 4.26 (2H, t), 7.45 (1H, d),  
7.78 (1H, d), 8.19 (1H, s), 9.25 (1H, s).

EXAMPLE 86

30 **8-[5-((S)-3-Methylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (85%) from the title compound of Preparation 10 and (S)-(-)-2-methylpiperazine following the procedure of example 1.

m.p. 163 °C

35  $\delta$  (DMSO-d<sub>6</sub>): 0.93 (3H, d), 0.98 (3H, t), 1.00 (3H, t),  
1.83 (4H, m), 2.15 (1H, m), 2.70 (2H, m), 2.90 (1H, m),



3.41 (4H, m), 4.18 (2H, t), 4.26 (2H, t), 7.45 (1H, d),  
7.78 (1H, d), 8.19 (1H, s), 9.25 (1H, s).

EXAMPLE 87

5 **8-[5-(3-Dimethylaminoazetidine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (82%) from the title compound of Preparation 10 and azetidin-3-yl dimethylamine following the procedure of example 1.

m.p. 213 °C

10  $\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.01 (3H, t), 1.84 (4H, m), 2.97 (1H, m), 3.36 (6H, s), 3.45 (2H, t), 3.78 (2H, t), 4.19 (2H, t), 4.29 (2H, t), 7.49 (1H, d), 7.88 (1H, d),  
15 8.25 (1H, s), 9.27 (1H, s), 13.79 (1H, s).

EXAMPLE 88

**N-(3-Dimethylaminopropyl)-3-(oxopropyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (69%) from the title compound of Preparation 10 and N,N-dimethyl-1,3-propanediamine following the procedure of example 1.

m.p. 197 °C

25  $\delta$  (DMSO-d<sub>6</sub>): 0.94 (3H, t), 0.97 (3H, t), 1.49 (2H, m), 1.82 (4H, m), 2.07 (6H, s), 2.21 (2H, t), 2.76 (2H, t), 4.17 (2H, t), 4.23 (2H, t), 7.40 (1H, d), 7.65 (1H, bs), 7.81 (1H, d), 8.30 (1H, s), 9.22 (1H, s).

30 EXAMPLE 89

**8-[5-((1S,4S)-5-Methyl-2,5-diazabicyclo[2.2.1]heptane-2-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

A mixture of the title compound of Example 83 (0.51 g, 1.0 mmol), formaldehyde (0.5 mL, 6.2 mmol, 37%) and formic acid (0.3 mL) was stirred at 80° C for 2 h. The reaction mixture was concentrated under reduced pressure,

10057847.012502  
diluted with dichloromethane, washed with aqueous solution  
of sodium bicarbonate and water, dried (MgSO<sub>4</sub>) and  
evaporated under reduced pressure. The resulting crude  
residue was purified by Flash Column Chromatography (SiO<sub>2</sub>,  
5 dichloromethane-ethanol-ammonium hydroxide 140:8:1) to  
give the title compound (0.22 g, 42%) as a white solid..

m.p. 194 °C

10  $\delta$  (DMSO-d<sub>6</sub>): 0.98 (7H, m), 1.60 (1H, d), 1.85 (4H, m),  
2.24 (3H, s), 2.54 (1H, d), 2.70 (1H, d), 2.99 (1H, d),  
3.32 (s, 1H), 3.39 (1H, d), 4.23 (5H, m), 7.44 (1H, d),  
7.89 (1H, d), 8.30 (1H, s), 8.24 (1H, s).

#### EXAMPLE 90

15 **8-[5-(4-Ethylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (66%) from the title  
compound of Preparation 10 and N-ethylpiperazine following  
the procedure of example 1.

m.p. 192 °C

20  $\delta$  (DMSO-d<sub>6</sub>): 0.96 (9H, m), 1.84 (4H, m), 2.30 (2H, q),  
2.43 (4H, m), 2.93 (4H, m), 4.19 (2H, t), 4.27 (2H, t),  
7.47 (1H, d), 7.80 (1H, d), 8.20 (1H, s), 9.25 (1H, s).

#### EXAMPLE 91

25 **8-[5-(3-Dimethylaminomethylazetidine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (51%) from the title  
compound of Preparation 10 and the title compound of  
Preparation 35 following the procedure of example 1.

30 m.p. 172 °C

35  $\delta$  (DMSO-d<sub>6</sub>): 1.01 (6H, m), 1.87 (4H, m), 2.00 (6H, s),  
2.10 (2H, d), 2.59 (1H, m), 3.37 (2H, dd), 3.84 (2H, dd),  
4.20 (2H, t), 4.30 (2H, t), 7.51 (1H, d), 7.89 (1H, d),  
8.29 (1H, s), 9.26 (1H, s).

EXAMPLE 92

3-(5-Oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-  
i]purin-8-yl)-4-propoxy-*N*-(2-pyrrolidin-1-  
ylethyl)benzenesulfonamide

5            Obtained as a white solid (56%) from the title  
compound of Preparation 10 and 1-(2-aminoethyl)pyrrolidine  
following the procedure of example 1.

m.p. 198 °C

10             $\delta$  (DMSO-*d*<sub>6</sub>): 0.96 (3H, t), 0.99 (3H, t), 1.61 (4H, m),  
1.87 (4H, m), 2.4-2.5 (6H, m), 2.88 (2H, t), 4.20 (2H, t),  
4.26 (2H, t), 7.42 (1H, d), 7.66 (1H, bs), 7.86 (1H, d),  
8.32 (1H, s), 9.25 (1H, s).

EXAMPLE 93

15            8-[5-((3*R*,5*S*)-3,5-Dimethylpiperazine-1-sulfonyl)-2-  
propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-  
i]purin-5-one

20            Obtained as a white solid (83%) from the title  
compound of Preparation 10 and *cis*-2,6-dimethylpiperazine  
following the procedure of example 1.

m.p. 200 °C

25             $\delta$  (DMSO-*d*<sub>6</sub>): 0.93 (6H, d), 1.00 (3H, t), 1.03 (3H, t),  
1.6-1.9 (6H, m), 2.77 (2H, m), 3.50 (2H, m), 4.18 (2H, t),  
4.26 (2H, t), 7.45 (1H, d), 7.78 (1H, d), 8.20 (1H, s),  
9.25 (1H, s).

EXAMPLE 94

30            8-[5-((2*RS*,5*SR*)-2,5-Dimethylpiperazine-1-sulfonyl)-2-  
propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-  
i]purin-5-one

Obtained as a white solid (28%) from the title  
compound of Preparation 10 and *trans*-2,5-  
dimethylpiperazine following the procedure of example 1.

m.p. 117 °C

35             $\delta$  (DMSO-*d*<sub>6</sub>): 1.02 (9H, m), 1.18 (3H, d), 1.85 (4H, m),  
2.47 (1H, m), 1.8-3.1 (3H, m), 3.45 (2H, m), 4.18 (2H, t),

4.2 (2H, t), 7.43 (1H, d), 7.81 (1H, d), 8.29 (1H, s),  
9.25 (1H, s).

EXAMPLE 95

5 ***N*-(2-Dimethylaminoethyl)-*N*-ethyl-3-(5-oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (34%) from the title compound of Preparation 10 and *N,N*-dimethyl-*N'*-ethylethylenediamine following the procedure of example 1.  
10 m.p. 105 °C

δ (DMSO-*d*<sub>6</sub>): 0.99 (6H, m), 1.05 (3H, t), 1.85 (4H, m),  
2.16 (6H, s), 2.41 (2H, t), 3.21 (4H, m), 4.19 (2H, t),  
4.26 (2H, t), 4.41 (1H, d), 7.87 (1H, d), 8.30 (1H, s),  
15 9.25 (1H, s).

EXAMPLE 96

**8-[5-(4-Allylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one**

20 Obtained as a white solid (65%) from the title compound of Preparation 10 and 1-allyl-piperazine following the procedure of example 1.

m.p. 187 °C

δ (DMSO-*d*<sub>6</sub>): 0.96 (6H, m), 1.85 (4H, m), 2.43 (4H, m),  
25 2.92 (6H, m), 4.19 (2H, t), 4.27 (2H, t), 5.11 (2H, m),  
5.69 (1H, m), 7.47 (1H, d), 7.80 (1H, d), 8.19 (1H, s), 9.27  
(1H, s), 13.76 (1H, bs).

EXAMPLE 97

30 **8-{5-[(*S*)-(Hexahydropyrrolo[1,2-*a*]pyrazin-2-yl)sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*] purin-5-one**

Obtained as a white solid (65%) from the title compound of Preparation 10 and (*S*)-octahydropyrrolo[1,2-*a*]pyrazine following the procedure of example 1.  
35

m.p. 180 °C





Obtained as a white solid (62%) from the title compound of Preparation 10 and N-(3-aminopropyl)morpholine following the procedure of example 1.

m.p. 195 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 0.98 (3H, t), 1.52 (2H, m), 1.86 (4H, m), 2.22 (6H, m), 2.80 (2H, m), 3.48 (4H, m), 4.20 (2H, t), 4.26 (2H, t), 7.43 (1H, d), 7.65 (1H, t), 7.84 (1H, d), 8.32 (1H, s), 9.26 (1H, s), 13.58 (1H, bs).

10        EXAMPLE 104

**8-{5-[4-(2-Methoxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

15        Obtained as a white solid (67%) from the title compound of Preparation 10 and 1-(2-methoxyethyl)piperazine following the procedure of example 1.

m.p. 177 °C

20         $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 1.01 (3H, t), 1.86 (4H, m), 2.59 (6H, m), 2.91 (4H, m), 3.17 (3H, s), 3.35 (2H, t), 4.19 (2H, t), 4.27 (2H, t), 7.47 (1H, d), 7.78 (1H, d), 8.19 (1H, s), 9.27 (1H, s).

25        EXAMPLE 105

**8-{5-[4-(2-Hydroxyethyl)-[1,4]diazepane-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

30        Obtained as a white solid (67%) from the title compound of Preparation 10 and 2-(1,4-diazepan-1-yl)ethan-1-ol following the procedure of example 1.

m.p. 193 °C

35         $\delta$  (DMSO-d<sub>6</sub>): 0.98 (6H, m), 1.72 (2H, m), 1.87 (4H, m), 2.63 (2H, t), 2.72 (2H, m), 3.35 (10H, m), 4.23 (4H, m), 7.42 (1H, d), 7.83 (1H, d), 8.25 (1H, s), 9.26 (1H, s).

EXAMPLE 106

8-{5-[4-(2-Hydroxy-1-methylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

5            Obtained as a white solid (65%) from the title compound of Preparation 10 and 2-piperazin-1-ylpropan-1-ol following the procedure of example 1.

m.p. 216 °C

10             $\delta$  (DMSO-d<sub>6</sub>): 0.86 (3H, d), 0.95 (3H, t), 0.98 (3H, t), 1.85 (4H, m), 2.56 (4H, m), 2.89 (4H, m), 3.20 (1H, m), 3.39 (2H, m), 4.19 (2H, t), 4.27 (2H, t), 7.46 (1H, d), 7.79 (1H, d), 8.18 (1H, s), 9.25 (1H, s).

EXAMPLE 107

15            **N-(1-Ethylaminocyclohexylmethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy benzenesulfonamide**

20            Obtained as a white solid (71%) from the title compound of Preparation 10 and (1-aminomethylcyclohexyl)ethylamine following the procedure of example 1.

m.p. 201 °C

25             $\delta$  (DMSO-d<sub>6</sub>): 0.96 (9H, m), 1.34 (8H, m), 1.48 (2H, m), 1.84 (4H, m), 2.35 (2H, m), 2.72 (2H, s), 4.20 (4H, m), 7.37 (1H, d), 7.82 (1H, d), 8.36 (1H, s), 9.24 (1H, s).

EXAMPLE 108

30            8-{5-[4-(2-Hydroxy-1,1-dimethylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

Obtained as a white solid (85%) from the title compound of Preparation 10 and the title compound of Preparation 37 following the procedure of example 1.

m.p. 223 °C

35             $\delta$  (DMSO-d<sub>6</sub>): 0.88 (6H, s), 0.93 (3H, t), 1.01 (3H, t), 1.86 (4H, m), 2.63 (4H, m), 2.87 (4H, m), 3.20 (2H, bs),



3.34 (1H, bs), 4.20 (2H, t), 4.27 (2H, t), 7.47 (1H, d),  
7.76 (1H, d), 8.19 (1H, s), 9.25 (1H, s).

EXAMPLE 109

5 8-{2-Propoxy-5-[4-(2,2,2-trifluoroethyl)piperazine-1-sulfonyl]phenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

Obtained as a white solid (36%) from the title compound of Preparation 10 and 1-(2,2,2-trifluoroethyl)piperazine following the procedure of example 1.

m.p. 202 °C

10  $\delta$  (DMSO-d<sub>6</sub>): 0.88 (6H, s), 0.93 (3H, t), 1.01 (3H, t),  
1.86 (4H, m), 2.63 (4H, m), 2.87 (4H, m), 3.20 (2H, bs),  
3.34 (1H, bs), 4.20 (2H, t), 4.27 (2H, t), 7.47 (1H, d),  
15 7.76 (1H, d), 8.19 (1H, s), 9.25 (1H, s).

EXAMPLE 110

20 N-(1-Ethylaminocycloheptylmethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide

Obtained as a white solid (53%) from the title compound of Preparation 10 and (1-aminomethylcycloheptyl)ethylamine following the procedure of example 1.

25 m.p. 203 °C

$\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 1.00 (3H, t), 1.2-1.6 (12H, m), 1.86 (4H, m), 2.35 (2H, m), 2.68 (2H, m), 4.19 (2H, t), 4.22 (2H, t), 7.38 (1H, d), 7.82 (1H, d), 8.36 (1H, s), 9.19 (1H, s).

30

EXAMPLE 111

N-(1-Diethylaminocyclohexylmethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide

35 Obtained as a white solid (35%) from the title compound of Preparation 10 and (1-

aminomethylcyclohexyl)diethylamine following the procedure of example 1.

m.p. 192 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 1.0 (12H, m), 1.34 (10H, m), 1.83 (4H, m), 2.47 (4H, m), 3.06 (2H, s), 4.22 (4H, m), 7.39 (1H, d), 7.85 (1H, d), 8.31 (1H, s), 9.23 (1H, s).

#### EXAMPLE 112

10        ***N*-[2-(3,4-Dimethoxyphenyl)ethyl]-*N*-methyl-3-(5-oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (42%) from the title compound of Preparation 10 and 2-(3,4-dimethoxyphenyl)-*N*-methylethylamine following the procedure of example 1.

15        m.p. 92 °C

20         $\delta$  (DMSO-d<sub>6</sub>): 0.91 (3H, t), 0.99 (3H, t), 1.84 (4H, m), 2.72 (5H, m), 3.21 (2H, t), 3.33 (3H, s), 3.70 (3H, s), 4.15 (2H, t), 4.25 (2H, t), 6.74 (1H, d), 6.82 (1H, s), 6.84 (1H, d), 7.41 (1H, d), 7.80 (1H, d), 8.23 (1H, s), 9.25 (1H, s), 13.70 (1H, bs).

#### EXAMPLE 113

25        ***N*-(1-Diethylaminocycloheptylmethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (30%) from the title compound of Preparation 10 and (1-aminomethylcycloheptyl)diethylamine following the procedure of example 1.

m.p. 171 °C

30         $\delta$  (DMSO-d<sub>6</sub>): 1.0 (12H, m), 1.49 (12H, m), 1.84 (4H, m), 2.50 (4H, m), 3.05 (2H, s), 4.21 (4H, m), 7.38 (1H, d), 7.84 (1H, d), 8.31 (1H, s), 9.22 (1H, s).

#### EXAMPLE 114

35        ***N*-(1-Methyl-4-phenylpiperidin-4-ylmethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (54%) from the title compound of Preparation 10 and 4-aminomethyl-1-methyl-4-phenylpiperidine following the procedure of example 1.

m.p. 213 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.95 (3H, t), 0.99 (3H, t), 1.80 (6H, m), 2.04 (4H, m), 2.10 (3H, s), 2.51 (2H, bs), 2.82 (2H, d), 7.0-7.5 (7H, m), 7.73 (1H, d), 8.23 (1H, s), 9.22 (1H, s).

#### EXAMPLE 115

10        8-{5-[4-(3-Hydroxypropyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one

15        To a mixture of the title compound of Preparation 10 (40 mg, 0.09 mmol) and polymer bound morpholine (65 mg, 2.75 mmol/g based on nitrogen analysis) in dichloromethane (3 mL) was added 3-piperazin-1-ylpropan-1-ol (14.1 mg, 0.098 mmol) and the resulting mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was evaporated under reduced pressure.

20        The residue was triturated with diethyl ether and the precipitate was collected by filtration and dried under vacuum to yield the title compound (41 mg, 82%) as a white solid.

ESI/MS m/e: 559 ([M+H]<sup>+</sup>, C<sub>25</sub>H<sub>34</sub>N<sub>8</sub>O<sub>5</sub>S)

25        Retention Time (min.): 11.7

#### EXAMPLES 116-131

30        N,N-Dimethyl-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (116)

N-{1-[3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxyphenyl]sulfonylguanidine (117)

35        N-(2-Hydroxyethyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (118)

- 3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-(1H-[1,2,4]triazol-3-yl)benzenesulfonamide (119)
- 5 N-(2-Dimethylaminoethyl)-N-methyl-3-(oxopropyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (120)
- 3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-pyridin-4-ylmethylbenzenesulfonamide (121)
- 10 3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-(2-pyridin-2-ylethyl)benzenesulfonamide (122)
- N-(3-Imidazol-1-ylpropyl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (123)
- 15 N-Methyl-N-(1-methylpiperidin-4-yl)-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (124)
- 8-[5-(4-Isopropylpiperazine-1-sulfonyl)-2-propoxyphenyl]-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one (125)
- 20 N-Ethyl-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide (126)
- 25 3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxy-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide (127)
- N-(4-Hydroxy-1-methylpiperidin-4-ylmethyl)-N-methyl-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (128)
- 30 N-(4-Hydroxy-1-methylpiperidin-4-ylmethyl)-N-methyl-3-(5-oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonamide (129)
- 8-{2-Propoxy-5-[4-(2,2,2-trifluoroethanoyl)piperazine-1-sulfonyl]phenyl}-6-propyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one (130)
- 35

N-(1-{[3-(5-Oxo-6-propyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-4-propoxybenzenesulfonylamino]methyl}cycloheptyl)acetamide (131)

5 The title compounds were synthesized from the title compound of Preparation 10 following the procedure of example 115 and using the corresponding reactant, respectively. The ESI/MS data, HPLC retention times and yields are summarised in Table 3.

10

Example	Molecular Formula	ESI/MS m/e [M+H] <sup>+</sup>	Retention Time (min.)	Yield %
115	C <sub>25</sub> H <sub>34</sub> N <sub>8</sub> O <sub>5</sub> S	559	11.7	82
116	C <sub>20</sub> H <sub>25</sub> N <sub>7</sub> O <sub>4</sub> S	460	16.3	79
117	C <sub>19</sub> H <sub>23</sub> N <sub>9</sub> O <sub>4</sub> S	445	16.5	66
118	C <sub>20</sub> H <sub>25</sub> N <sub>7</sub> O <sub>5</sub> S	476	13.8	75
119	C <sub>20</sub> H <sub>22</sub> N <sub>10</sub> O <sub>4</sub> S	499	15.4	85
120	C <sub>23</sub> H <sub>32</sub> N <sub>8</sub> O <sub>4</sub> S	517	11.3	84
121	C <sub>24</sub> H <sub>26</sub> N <sub>8</sub> O <sub>4</sub> S	523	13.1	72
122	C <sub>25</sub> H <sub>28</sub> N <sub>8</sub> O <sub>4</sub> S	537	13.5	77
123	C <sub>24</sub> H <sub>29</sub> N <sub>9</sub> O <sub>4</sub> S	540	11.2	68
124	C <sub>25</sub> H <sub>34</sub> N <sub>8</sub> O <sub>4</sub> S	543	11.7	66
125	C <sub>25</sub> H <sub>34</sub> N <sub>8</sub> O <sub>4</sub> S	543	12.0	79
126	C <sub>25</sub> H <sub>33</sub> N <sub>7</sub> O <sub>5</sub> S	544	18.0	82
127	C <sub>27</sub> H <sub>38</sub> N <sub>8</sub> O <sub>4</sub> S	571	11.9	84
128	C <sub>26</sub> H <sub>36</sub> N <sub>8</sub> O <sub>5</sub> S	573	11.2	74
129	C <sub>26</sub> H <sub>36</sub> N <sub>8</sub> O <sub>5</sub> S	573	12.6	87
130	C <sub>24</sub> H <sub>27</sub> F <sub>3</sub> N <sub>8</sub> O <sub>5</sub> S	597	17.3	65
131	C <sub>28</sub> H <sub>38</sub> N <sub>8</sub> O <sub>5</sub> S	447	16.5	58

#### EXAMPLE 132

15 **6-Butyl-8-[5-(3-hydroxyazetidine-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (50%) from the title compound of Preparation 14 and azetidin-3-ol following the procedure of example 1.

20

m.p. 238 °C

5  $\delta$  (DMSO-d6): 0.95 (3H, t), 1.02 (3H, t), 1.39 (2H, m), 1.83 (4H, m), 3.36 and 3.39 (4H, 2d), 3.90 and 3.93 (4H, 2d), 4.24 (2H, t), 4.31 (2H, t), 5.74 (1H, d), 7.51 (1H, d), 7.88 (1H, d), 8.29 (1H, s), 9.26 (1H, s), 13.8 (1H, s).

EXAMPLE 133

**6-Butyl-8-[5-(piperazine-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

10 Obtained as a white solid (60%) from the title compound of Preparation 14 and piperazine following the procedure of example 1.

m.p. 147 °C

15  $\delta$  (DMSO-d6): 0.95 (3H, t), 1.02 (3H, t), 1.72 (2H, m), 1.85 (4H, m), 2.80 (2H, t), 2.85 (2H, t), 3.27 (4H, m), 4.20 (4H, m), 7.38 (1H, d), 7.79 (1H, d), 8.27 (1H, s), 9.20 (1H, s).

EXAMPLE 134

20 **3-(6-Butyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-i]purin-8-yl)-N-methyl-N-(1-methylazetidin-3-yl)-4-propoxybenzenesulfonamide**

25 Obtained as a white solid (19%) from the title compound of Preparation 14 and methyl(1-methylazetidin-3-yl)amine following the procedure of example 1.

m.p. 169 °C

30  $\delta$  (CDCl<sub>3</sub>): 1.02 (3H, t), 1.16 (3H, t), 1.48 (2H, m), 1.89 (2H, m), 2.08 (2H, m), 2.30 (3H, s), 2.75 (3H, s), 3.06 (2H, t), 3.53 (2H, t), 4.02 (1H, m), 4.39 (4H, m), 7.19 (1H, d), 7.26 (1H, s), 7.80 (1H, d), 8.74 (1H, s), 8.96 (1H, s).

EXAMPLE 135

35 **6-Butyl-8-[5-(3-dimethylaminomethylazetidine-1-sulfonyl)-2-propoxyphenyl]-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

Obtained as a white solid (56%) from the title compound of Preparation 14 and the title compound of Preparation 33 following the procedure of example 1.

m.p. 198 °C

5         $\delta$  (DMSO-d<sub>6</sub>): 0.96 (3H, t), 1.03 (3H, t), 1.37 (2H, m),  
1.80 (2H, m), 1.87 (2H, m), 1.99 (6H, s), 2.1 (2H, d),  
2.51 (1H, m), 3.36 (2H, m), 3.83 (2H, t), 4.25 (2H, t),  
4.31 (2H, t), 7.50 (1H, d), 7.88 (1H, d), 8.30 (1H, s),  
9.24 (1H, s).

10

#### EXAMPLE 136

**6-Butyl-8-(5-{3-[(2-hydroxyethyl)methylamino]azetidine-1-sulfonyl}-2-propoxyphenyl)-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

15        Obtained as a white solid (54%) from the title compound of Preparation 14 and 2-(azetidin-3-ylmethylamino)ethanol following the procedure of example 1.

m.p. 162 °C

20         $\delta$  (DMSO-d<sub>6</sub>): 0.46 (4H, m), 1.33 (2H, m), 1.80 (4H, m),  
1.90 (3H, s), 2.18 (2H, t), 3.21 (1H, m), 3.47 (2H, t),  
3.75 (2H, t), 4.24 (6H, m), 7.47 (1H, d), 7.86 (1H, d),  
8.26 (1H, s), 9.23 (1H, s), 13.72 (1H, bs).

#### 25        EXAMPLE 137

**6-Butyl-8-{5-[4-(2-hydroxy-1-methylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one**

30        Obtained as a white solid (65%) from the title compound of Preparation 14 and 2-piperazin-1-ylpropan-1-ol following the procedure of example 1.

m.p. 221 °C

35         $\delta$  (DMSO-d<sub>6</sub>): 0.86 (3H, d), 0.95 (3H, t), 1.00 (3H, t),  
1.38 (2H, m), 1.83 (4H, m), 2.59 (4H, m), 2.89 (4H, m),  
3.21 (1H, m), 3.39 (2H, m), 4.25 (4H, m), 7.46 (1H, d),  
7.79 (1H, d), 8.21 (1H, s), 9.25 (1H, s), 13.7 (1H, s).

EXAMPLE 138

6-Butyl-8-{5-[4-(2-hydroxy-1,1-dimethylethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one

Obtained as a white solid (82%) from the title compound of Preparation 14 and the title compound of Preparation 37 following the procedure of example 1.

m.p. 237 °C

$\delta$  (DMSO-*d*<sub>6</sub>): 0.87 (6H, s), 0.95 (3H, t), 1.02 (3H, t), 1.38 (2H, m), 1.82 (4H, m), 2.62 (4H, m), 2.86 (4H, m), 3.20 (2H, s), 4.25 (4H, m), 7.46 (1H, d), 7.77 (1H, d), 8.20 (1h, s), 9.24 (1H, s).

EXAMPLES 139-142

*N,N*-Bis-(2-hydroxyethyl)-3-(6-isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide (139)

3-(6-Isobutyl-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-*N*-(4-methylpiperazin-1-yl)-4-propoxybenzenesulfonamide (140)

8-{5-[4-(2-Hydroxyethyl)piperidine-1-sulfonyl]-2-propoxyphenyl}-6-isobutyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one (141)

8-(5-{4-[2-(2-Hydroxyethoxy)ethyl]piperazine-1-sulfonyl}-2-propoxyphenyl)-6-isobutyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one (142)

The title compounds were synthesized from the title compound of Preparation 30 following the procedure of example 115 and using the corresponding reactant respectively. The ESI/MS data, HPLC retention times and yields are summarised in Table 4.



TABLE 4

Example	Molecular Formula	ESI/MS m/e [M+H] <sup>+</sup>	Retention Time (min.)	Yield %
139	C <sub>23</sub> H <sub>31</sub> N <sub>7</sub> O <sub>6</sub> S	534	15.1	62
140	C <sub>24</sub> H <sub>33</sub> N <sub>9</sub> O <sub>4</sub> S	544	13.1	78
141	C <sub>26</sub> H <sub>35</sub> N <sub>7</sub> O <sub>5</sub> S	558	18.7	75
142	C <sub>27</sub> H <sub>38</sub> N <sub>8</sub> O <sub>6</sub> S	603	13.7	77

## EXAMPLE 143

5 ***N*-(2-Hydroxyethyl)-3-[6-(2-methoxyethyl)-5-oxo-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl]-4-propoxy-*N*-propylbenzenesulfonamide**

Obtained as a white solid (43%) from the title compound of Preparation 34 and 2-propylaminoethanol following the procedure of example 1.

m.p. 183 °C

δ (DMSO-d<sub>6</sub>): 0.82 (3H, t), 0.99 (3H, t), 1.52 (2H, m), 1.87 (2H, m), 3.13 (4H, m), 3.30 (3H, s), 3.51 (2H, t), 3.79 (2H, t), 4.28 (2H, t), 4.41 (2H, t), 7.43 (1H, d), 7.89 (1H, d), 8.31 (1H, s), 9.29 (1H, s).

## EXAMPLE 144

20 ***3*-[6-(2-Methoxyethyl)-5-oxo-6,9-dihydro-5*H*-[1,2,4]triazolo[3,4-*i*]purin-8-yl]-*N*-(2-morpholin-4-yl-ethyl)-4-propoxybenzenesulfonamide**

Obtained as a white solid (48%) from the title compound of Preparation 34 and 2-morpholin-4-ylethylamine following the procedure of example 1.

m.p. 171 °C

25 δ (DMSO-d<sub>6</sub>): 0.98 (3H, t), 1.87 (2H, n), 2.27 (6H, m), 2.89 (2H, m), 3.29 (3H, s), 3.48 (4H, m), 3.79 (2H, t), 4.27 (2H, t), 4.42 (2H, t), 7.43 (1H, d), 7.61 (1H, t), 7.87 (1H, d), 8.34 (1H, s), 9.28 (1H, s).

30

EXAMPLE 145

8-{5-[4-(3-Hydroxypropyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-6-(2-methoxyethyl)-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one

5        Obtained as a white solid (32%) from the title compound of Preparation 34 and 3-piperazin-1-ylpropan-1-ol following the procedure of example 1.

m.p. 171 °C

10         $\delta$  (DMSO-*d*<sub>6</sub>): 0.99 (3H, t), 1.50 (2H, m), 1.87 (2H, m), 2.36 (2H, m), 2.45 (4H, m), 2.92 (4H, m), 3.30 (3H, s), 3.78 (2H, t), 4.28 (2H, t), 4.41 (2H, t), 7.48 (1H, d), 7.78 (1H, d), 8.21 (1H, s), 9.28 (1H, s).

EXAMPLE 146

15        3-[6-(2-Methoxyethyl)-5-oxo-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl]-N-(3-morpholin-4-ylpropyl)-4-propoxybenzenesulfonamide

20        Obtained as a white solid (47%) from the title compound of Preparation 34 and 3-morpholin-4-ylpropylamine following the procedure of example 1.

m.p. 149 °C

25         $\delta$  (DMSO-*d*<sub>6</sub>): 0.96 (3H, t), 1.49 (2H, m), 1.84 (2H, m), 2.19 (6H, m), 2.78 (2H, m), 3.27 (3H, s), 3.45 (4H, m), 3.76 (2H, t), 4.25 (2H, t), 4.39 (2H, t), 7.41 (1H, d), 7.62 (1H, t), 7.81 (1H, d), 8.31 (1H, s), 9.25 (1H, s).

EXAMPLES 147-149

30        *N,N*-Bis-(2-hydroxyethyl)-3-(5-oxo-6-pentyl-6,9-dihydro-5H-[1,2,4]triazolo[3,4-*i*]purin-8-yl)-4-propoxybenzenesulfonamide (147)

8-{5-[4-(2-Hydroxyethyl)piperidine-1-sulfonyl]-2-propoxyphenyl}-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one (148)

35        8-(5-{4-[2-(2-Hydroxyethoxy)ethyl]piperazine-1-sulfonyl}-2-propoxyphenyl)-6-pentyl-6,9-dihydro-[1,2,4]triazolo[3,4-*i*]purin-5-one (149)

5 The title compounds were synthesized from the title compound of Preparation 32 following the procedure of example 115 and using the corresponding reactant respectively. The ESI/MS data, HPLC retention times and yields are summarised in Table 5.

TABLE 5				
Example	Molecular Formula	ESI/MS m/e [M+H] <sup>+</sup>	Retention Time (min.)	Yield %
147	C <sub>24</sub> H <sub>33</sub> N <sub>7</sub> O <sub>6</sub> S	548	16.7	85
148	C <sub>27</sub> H <sub>37</sub> N <sub>7</sub> O <sub>5</sub> S	572	20.3	65
149	C <sub>28</sub> H <sub>40</sub> N <sub>8</sub> O <sub>6</sub> S	617	15.0	72

10 The following examples illustrate pharmaceutical compositions according to the present invention and procedure for their preparation.

COMPOSITION EXAMPLE 1

15 50,000 capsules each containing 100 mg of active ingredient were prepared according to the following formulation:

Active ingredient	5 Kg
20 Lactose monohydrate	10 Kg
Colloidal silicone dioxide	0.1 Kg
Corn starch	1 Kg
Magnesium stearate	0.2 Kg

25 Procedure

The above ingredients were sieved through a 60 mesh sieve, and were loaded into a suitable mixer and filled into 50,000 gelatine capsules.

30 COMPOSITION EXAMPLE 2

50,000 Tablets each containing 50 mg of active ingredient were prepared from the following formulation:

	Active ingredient	2.5 Kg
	Microcrystalline cellulose	1.95 Kg
	Spray dried lactose	9.95 Kg
	Carboxymethyl starch	0.4 Kg
5	Sodium stearyl fumarate	0.1 Kg
	Colloidal silicon dioxide	0.1 Kg

#### Procedure

- 10 All the powders were passed through a screen with an aperture of 0.6 mm, then mixed in a suitable mixer for 20 minutes and compressed into 300 mg tablets using 9 mm disc and flat bevelled punches. The disintegration time of the tablets was about 3 minutes.

10037647-013303